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Primarily based on the tissue specimens collected through three clinical trials 
in breast cancer patients, two separate projects were conducted. The first 
project studied the prognostic and predictive roles of CAF/ECM and integrin 
proteins to chemotherapy response. 100 patients with advanced breast cancer 
were treated with 6 cycles of alternating sequential doxorubicin and docetaxel. 
Immunohistochemistry (IHC) staining for CAF/ECM (THBS1, TNC, FN, α-
SMA and SPARC) and integrin (α6, α9 and β1) proteins was performed on 
pre- and post-treatment core biopsies. We found that high expression of 
combined baseline CAF/ECM protein predicted independently for poor 
progression-free (HRadjusted 2.22, 95% CI 1.06-4.64) and overall survival 
(HRadjusted 5.94, 95% CI 2.25-15.71); high baseline integrin α6 and β1 were 
independent predictors for poor progression-free survival (HRadjusted 4.34, 95% 
CI 1.05-17.90, p=0.042 for integrin α6; HRadjusted 4.71, 95% CI 1.05-21.15, 
p=0.043 for integrin β1). After chemotherapy, increased expression of THBS1 
and TNC compared to baseline was seen in intrinsically resistant tumors 
(p<0.05); increased expression of THBS1, TNC, FN, SPARC, α-SMA and 
integrin α6 relative to baseline was seen in patients with pathological lymph 
node involvement (p<0.05 for all). The association between THBS1, TNC and 
integrin α6 and chemoresistance was further confirmed in an independent 
cohort of 31 patients. Functional studies showed that both exogenous THBS1 
and TNC protected MCF-7 cells against proliferation inhibition induced by 




The second project explored the underlying mechanisms of the anti-tumoral 
effects of simvastatin in breast cancer. 15 female patients with newly 
diagnosed primary breast cancer received 5-38 days of simvastatin at a dose of 
20mg daily before definitive breast cancer surgery. IHC staining was 
performed on pre- and post-treatment tumor biopsies, respectively. In clinical 
samples, simvastatin led to increase in cleaved caspase-3 (p=0.002) and 
decreased trend for Ki67 (p=0.245). Simvastatin markedly suppressed 
PI3K/Akt/mTOR signalling by activating PTEN (p=0.005) and by 
dephosphorylating Akt (p=0.002) and S6RP (p=0.033); it also inhibited 
MAPK/ERK pathway by dephosphorylating c-Raf (p=0.018) and ERK1/2 
(p=0.002). In breast cancer cells MCF-7, MDA-MB-231 and BT-549, 
simvastatin treatment consistently induced apoptosis and inhibited 
proliferation. Concordantly, simvastatin strongly suppressed PI3K/Akt/mTOR 
pathway by enhancing PTEN expression and by further sequentially 
dephosphorylating downstream cascades including Akt, mTOR, p70S6K, 
S6RP and 4E-BP1. Furthermore, simvastatin significantly inhibited 
MAPK/ERK pathway by dephosphorylating sequential cascades such as c-Raf, 
MEK1/2 and ERK1/2. Simvastatin-induced anti-tumoral effects and 
deactivation of PI3K/Akt and MAPK/ERK signalling were reversed by 
metabolic products of the mevalonate pathway, such as mevalonate, farnesyl 
pyrophosphate and geranylgeranyl pyrophosphate.  
In conclusion, the first project showed the up-regulation in CAF/ECM 
(THBS1, TNC, FN and α-SMA) and integrin α6 proteins following 
neoadjuvant chemotherapy was associated with chemotherapy resistance. 
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THBS1 and TNC protected breast cancer cells against proliferation inhibition 
induced by docetaxel through activating integrin β1/mTOR pathway. 
Therapies targeting integrin β1/mTOR pathway may be a promising strategy 
to overcome chemotherapy resistance. The second project demonstrated that 
simvastatin promoted apoptosis and suppressed proliferation of breast cancer 
through deactivating signalling pathways of PI3K/Akt/mTOR and 
MAPK/ERK via inhibition of mevalonate pathway. These findings shed light 





LIST OF TABLES 
Table 3.1 Functional roles of 5 selected CAF/ECM proteins in breast cancer 
progression ....................................................................................................... 24 
Table 3.2 Dilutions and manufacturers for antibodies and cut-offs for 
immunohistochemistry staining of CAF/ECM/integrin project ...................... 32 
Table 3.3 Antibodies used for Western blots analyses of CAF/ECM/integrin 
project .............................................................................................................. 35 
Table 3.4 Methods used for statistical analysis of CAF/ECM/integrin project
.......................................................................................................................... 37 
Table 3.5 Clinicopathological characteristics of the primary cohort ............... 41 
Table 3.6 Univariate and multivariate analysis of correlation between baseline 
proteins expression of CAF/ECM and progression-free and overall survival in 
the primary cohort ............................................................................................ 47 
Table 3.7 Relation between baseline proteins expression by CAF/ECM and 
tumor ER status ................................................................................................ 56 
Table 3.8 Association between changes of CAF/ECM protein expression 
following chemotherapy and tumor ER status in the primary cohort .............. 57 
Table 3.9 Relation between baseline proteins expression by CAF/ECM and 
tumor Her2 status ............................................................................................. 58 
Table 3.10 Changes of CAF/ECM protein expression following chemotherapy 
and their association with tumor Her2 status ................................................... 59 
Table 3.11 Relation between baseline proteins expression by CAF/ECM and 
intrinsic response following chemotherapy ..................................................... 60 
Table 3.12 Relation between baseline proteins expression by CAF/ECM and 
pathological lymph node involvement at surgery following chemotherapy .... 63 
Table 3.13 Clinicopathological characteristics of the validation cohort .......... 65 
XVI 
 
Table 3.14 Relation between baseline expression of integrin proteins and ER 
status, Her2 status and intrinsic response in the primary cohort...................... 72 
Table 3.15 Univariate and multivariate analysis of baseline integrin proteins 
for progression-free and overall survival in the primary cohort ...................... 76 
Table 3.16 Relation between baseline integrin proteins and pathological lymph 
node involvement at surgery in the primary cohort ......................................... 85 
Table 4.1 Clinicopathological characteristics of breast cancer patients enrolled 
into a window-of-opportunity study with simvastatin ................................... 112 
Table 4.2 Antibodies used for immunohistochemistry staining of simvastatin 
project ............................................................................................................ 113 







LIST OF FIGURES 
Figure 1.1 Structure and workflow of the whole thesis. .................................... 4 
Figure 2.1. Cooperation between integrin and growth factor signalling ......... 11 
Figure 2.2  Mevalonate metabolism................................................................. 14 
Figure 2.3  MAPK and the PI3K pathways ..................................................... 18 
Figure 2.4 Role of PI3K/AKT in ECM/integrin-mediated chemotherapy 
resistance .......................................................................................................... 22 
Figure 3.1  Workflow of the clinical and functional studies for CAF/ECM 
project .............................................................................................................. 27 
Figure 3.2  Diagram of comparison between CAF/ECM and integrin proteins
.......................................................................................................................... 38 
Figure 3.3 Schema of the workflow for the Result Section of 
CAF/ECM/integrin project .............................................................................. 40 
Figure 3.4 Immunoreactivity of proteins expressed by CAF/ECM in baseline 
tumor with matched adjacent normal tissue..................................................... 43 
Figure 3.5 Association between baseline CAF/ECM protein expression and 
progression-free and overall survival ............................................................... 46 
Figure 3.6 Association between CAF/ECM protein expression at cycle 1 and 
progression-free and overall survival ............................................................... 50 
Figure 3.7 Association between CAF/ECM protein expression at cycle 2 and 
progression-free and overall survival ............................................................... 53 
Figure 3.8 Increase in CAF/ECM protein expression following neoadjuvant 
chemotherapy in the primary cohort ................................................................ 55 
XVIII 
 
Figure 3.9 Comparison of changes in THBS1 and TNC expression after cycle 
1 and 2 chemotherapy relative to baseline in ER positive and negative 
subgroups in the primary cohort ...................................................................... 57 
Figure 3.10  Comparison of changes in CAF/ECM proteins after cycle 1 and 
cycle 2 chemotherapy relative to baseline in intrinsically sensitive (IS) and 
resistant (IR) tumors in the primary cohort ...................................................... 61 
Figure 3.11 Comparison of changes in CAF/ECM proteins expression after 
chemotherapy relative to baseline in pathological lymph node positive and 
negative tumors in the primary cohort ............................................................. 64 
Figure 3.12 Association between increased THBS1 and TNC expression and 
chemoresistance following neoadjuvant chemotherapy in the validation cohort
.......................................................................................................................... 67 
Figure 3.13 Schema of clinical findings for CAF/ECM proteins in breast 
cancer ............................................................................................................... 69 
Figure 3.14 Representative pictures for low and high expression of each 
individual integrin subunit protein ................................................................... 73 
Figure 3.15 Association between baseline tumor expression of integrin 
proteins and progression-free and overall survival .......................................... 75 
Figure 3.16 Association between integrin proteins expression after 1 cycle of 
chemotherapy and progression-free and overall survival ................................ 78 
Figure 3.17 Association between integrin proteins expression at cycle 2 and 
progression-free and overall survival ............................................................... 80 
Figure 3.18 Increased expression of integrin proteins following neoadjuvant 
chemotherapy in the primary cohort ................................................................ 83 
Figure 3.19 Association between integrin proteins and pathological lymph 
node involvement in the primary cohort .......................................................... 85 
Figure 3.20 Association between integrin α6 and chemoresistance in the 
validation cohort .............................................................................................. 87 
XIX 
 
Figure 3.21 Association between baseline integrin α6 expression and survival 
in the validation cohort .................................................................................... 88 
Figure 3.22  Schema of clinical findings for integrin proteins in breast cancer.
.......................................................................................................................... 90 
Figure 3.23 Exogenous THBS1 and TNC protected MCF-7 cells against 
growth inhibition induced by docetaxel ........................................................... 93 
Figure 3.24 THBS1 and TNC protected MCF-7 cells against proliferation 
inhibition by docetaxel through activating integrin β1/mTOR pathway and 
deregulating cell cycle proteins ....................................................................... 94 
Figure 3.25 Schema of the mechanisms by which THBS1/TNC regulates 
chemotherapy resistance in breast cancer. ....................................................... 95 
Figure 4.1  Schema for patients, materials and methods in simvastatin project.
........................................................................................................................ 111 
Figure 4.2 Simvastatin induced apoptosis and inhibited proliferation in a 
window-of-opportunity trial of breast cancer ................................................ 117 
Figure 4.3 Simvastatin deactivated PI3K/Akt/mTOR pathway in a window-of-
opportunity trial of breast cancer ................................................................... 118 
Figure 4.4 Simvastatin deactivated MAPK/ERK pathway in a window-of-
opportunity trial of breast cancer ................................................................... 119 
Figure 4.5 Association between apoptosis induction and dephosphorylation of 
PI3K/Akt/mTOR and MAPK/ERK pathway and treatment duration of 
simvastatin ..................................................................................................... 122 
Figure 4.6 Simvastatin induced apoptosis in breast cancer cells ................... 124 
Figure 4.7 Simvastatin inhibited proliferation in breast cancer cells............. 126 
Figure 4.8 Simvastatin deactivated PI3K/Akt/mTOR pathways in breast 
cancer cells ..................................................................................................... 128 
XX 
 
Figure 4.9 Simvastatin deactivated MAPK/ERK pathways in breast cancer 
cells ................................................................................................................ 130 
Figure 4.10 Simvastatin-induced apoptosis was blocked by mevalonate, FPP 
and GGPP....................................................................................................... 132 
Figure 4.11 Simvastatin-inhibited cell growth was blocked by mevalonate, 
FPP and GGPP ............................................................................................... 133 
Figure 4.12 Simvastatin-deactivated PI3K/Akt and MAPK/ERK pathways 
were blocked by mevalonate, FPP and GGPP ............................................... 134 






LIST OF ABBREVIATIONS 
CAF cancer-associated fibroblasts 
CO2 carbon dioxide 
CS-FBS     charcoal stripped fatal bovine serum 
CI confidence interval 
DAB 3-3'-diaminobenzidine 
DMSO dimethyl sulfoxide 
DMEM       Dulbecco’s Modified Eagle Medium 
EGFR epidermal growth factor receptor 
ER estrogen receptors 
EDTA ethylenediaminetetraacetic acid 
ECM extracellular matrix 
ERK   extracellular signal regulated kinase 
FPP farnesyl pyrophosphate 
FBS fetal bovine serum 
FN fibronectin 
FAK focal adhesion kinase 
GGPP geranylgeranyl pyrophosphate 
GTPases guanosine triphosphatases 
HR hazard ratio 
HER2 human epidermal growth factor receptor 2  




IR intrinsically resistant 
IS intrinsically sensitive 
LN lymph node 
mTOR mammalian target of rapamycin  
mTORC1 mTOR complex 1 
MMPs matrix metalloproteinases 
MEK mitogen-activated protein kinase 
MW molecular weight 
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium 
OS overall survival  
PLN pathological lymph node 
PBS phosphate buffered saline 
PBST phosphate buffered saline with tween-20 
PIP2 phosphatidylinositol-4,5-bisphosphate 
PIP3 phosphatidylinositol-3,4,5-trisphosphate 
PTEN phosphatase and tensinhomolog 
PI3K phosphoinositide 3-kinases 
PVDF polyvinylidene fluoride 
PR progesterone receptor 
PFS progression-free survival 
p21   cyclin-dependent kinase inhibitor 1 
p27 cyclin-dependent kinase inhibitor 1B 
RTK receptor tyrosine kinase 
XXIII 
 
RT room temperature 
SPARC secreted protein acidic and rich in cysteine 
α-SMA smooth muscle actin-α  
NaCl sodium chloride 
SDS sodium dodecyl sulphate 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
TNC tenascin C 
THBS1 Thrombospondin 1 
TMA tissue microarray   
TBS Tris buffered saline 




CHAPTER 1. RATIONALE AND AIMS 
I am a research pathologist working in a breast cancer experimental 
therapeutics program, led by A/Prof Lee Soo Chin. Using the neoadjuvant 
model, A/Prof Lee has completed several therapeutic clinical trials in breast 
cancer, with collection of serial pre- and post-treatment tumor biopsies. 
Therefore, by incorporating my pathological expertise and research materials 
made available to me through these clinical trials, my projects were based 
primarily on studying pathology specimens from clinical trials, followed by 
functional work using breast cancer cell lines to understand underlying 
mechanisms of observations in the clinical specimens. For this thesis, I carried 
out two separate projects, one on understanding the role of cancer-associated 
fibroblasts (CAF)/extracellular matrix (ECM) proteins and their receptors 
(integrins) in chemotherapy response using tissue specimens from two 
neoadjuvant chemotherapy clinical trials, and one on understanding the anti-
tumoral effects of simvastatin using serial tissue samples obtained from a 
window-of-opportunity clinical trial. 
Cell adhesion-mediated drug resistance is the primary response of tumor to 
apoptosis induced by conventional chemotherapy or radiotherapy and it is 
mainly regulated by the interaction between the ECM in the tumor 
microenvironment and integrins on the surface of tumor cells (1). ECM is 
mainly secreted by CAF, which plays an important role in tumor progression 
and chemotherapy response (2-4). Integrins are α/β heterodimeric membrane 
receptors and their binding to specific ECM proteins facilitates cell adhesion 
2 
 
and intracellular signalling and thus regulates a variety of cellular responses 
such as migration, differentiation, proliferation and drug response (2). Early 
changes in both CAF/ECM and integrin proteins following initial exposure to 
chemotherapy drug and their association with chemoresponse have not been 
studied in depth, particularly in clinical specimens. Previously, our group has 
quantified changes of proteins with iTRAQ based LC-MS/MS using pooled 
samples that were intrinsically sensitive or resistant to doxorubicin or 
docetaxel respectively in a neoadjuvant doxorubicin and docetaxel based 
clinical trial. The analysis showed that some ECM proteins were up-regulated 
after 1 cycle of chemotherapy in tumors that were intrinsically resistant to 
doxorubicin or docetaxel, such as thrombospondin 1 (THBS1), tenascin C 
(TNC) and fibronectin (FN), but not in intrinsically sensitive ones 
(unpublished data). Based on these findings, the purpose of the first part of the 
thesis (CAF/ECM/integrin project) was to determine if neoadjuvant 
chemotherapy would induce changes in the expression of a panel of 
CAF/ECM and integrin proteins using immunohistochemistry and to further 
determine if these changes would be associated with clinical outcomes.  
Another area of emerging research interest in breast cancer is the anti-tumoral 
effects of statins. Statins are small-molecule inhibitors of 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase, an enzyme that catalyses 
HMG-CoA conversion to mevalonate and enables subsequent cholesterol 
synthesis and protein prenylation. Ras must undergo post-translational 
prenylation by intermediate products of mevalonate pathway to enable its 
translocation from cytoplasm to cell membrane. Therefore, through inhibition 
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of prenylation of Ras, statins may suppress extensive downstream signalling 
pathways of Ras, which are commonly abrogated in many types of cancer. A 
window-of-opportunity clinical trial has been conducted with collection of 
pre- and post-treatment tumor specimens following simvastatin treatment, 
which allows us to prospectively study the biological effects of simvastatin on 
breast cancer. The biological alterations following statins treatment in 
prospective clinical trials, particularly their effects on downstream effectors of 
Ras pathway, are lacking. Thus, the aims of the second part of the thesis 
(simvastatin project) were to determine 1) if simvastatin would regulate 
apoptosis and proliferation of breast cancer; 2) if simvastatin would regulate 
Ras downstream signalling pathways of breast cancer, including 
PI3K/Akt/mTOR and MAPK/ERK; and 3) if anti-cancer effects of simvastatin 
are mediated through inhibiting the mevalonate pathway. 
In summary, as shown in Figure 1.1, by using both clinical specimens from 
three clinical trials and breast cancer cell lines, a panel of CAF/ECM and 
integrin proteins were evaluated for their prognostic and predictive role in 
breast cancer; the underlying mechanisms of anti-tumoral effects of 
simvastatin were studied by focusing on the mevalonate pathway as well as 
PI3K/Akt/mTOR and MAPK/ERK signalling. These findings shed light on the 
biological roles of both CAF/ECM and integrin proteins in chemotherapy 
resistance as well as the underlying mechanisms by which simvastatin 








CHAPTER 2. INTRODUCTION 
2.1 Breast Cancer 
2.1.1 Definition and Epidemiology 
Breast cancer origins from breast tissues which consist of lobules and ducts. 
Breast cancer is the most common malignancy and the leading cause of 
cancer-related death in women worldwide (3). 20% of these patients will 
develop metastasis during the course of the disease, which is the major cause 
of death in breast cancer patients. 
2.1.2 Histopathological Classification  
The majority of breast cancers are invasive carcinoma. The two most common 
histological subtypes of breast cancers are invasive ductal and lobular 
carcinoma, accounting for 80% and 10-20% of invasive carcinoma 
respectively. Other minor subtypes include tubular, mucinous, medullary, 
papillary, micropapillary and metaplastic lesions (5%).  
2.1.3 Molecular Subtypes 
Increasing evidence suggests that breast cancer is not a single disease but a 
highly heterogeneous condition with differences at the molecular, 
histopathological and clinical levels, respectively. DNA microarray 
technology is able to reveal molecular differences. Based on the presence or 
absence of estrogen receptors (ER+/ER-), progesterone receptors (PR+/PR-) 
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and human epidermal growth factor receptor 2 (Her2+/Her2-), breast cancer is 
classified into 4 subtypes, namely luminal A (ER+ and/or PR+ and Her2-), 
luminal B (ER+ or PR+ and Her+), basal-like (ER-, PR-, and Her2-) and  Her2 
enriched (ER-, PR- and Her2+) subtypes. Prognosis and response to treatment 
among these 4 subtypes differ (4). Basal-like and Her2 subtypes are associated 
with worst prognosis, whereas the luminal-type tumors had a more favourable 
clinical outcome (5, 6). The distinct molecular classes also show different 
degrees of chemotherapy sensitivity; basal-like and Her2 subtypes of breast 
cancer are more sensitive to neoadjuvant anthracycline and taxane-based 
chemotherapy than luminal subtype (7). Her2 subtype is resistant to endocrine 
therapy and associated with poor clinical outcome, when compared with ER+ 
breast tumors (8-10). However, the use of anti-Her2 based therapies with 
either monoclonal antibodies or small molecule tyrosine kinase inhibitors, has 
improved its treatment response and survival. Following the discovery of the 
above-mentioned subtypes of breast cancer, claudin-low subtype (6% of breast 
cancer) is described, (11). Claudin-low tumors lack the expression of luminal 
markers and highly express mesenchymal markers, which are frequently found 
in the residual breast tumor tissue after conventional treatment (12). 
2.1.4 Prognostic and Predictive Biomarkers  
Well-established prognostic biomarkers of breast cancer include patient age, 
tumour grade, tumour size, lymph node involvement and metastasis, 
histological subtype, status of ER, PR and Her2 and lymphovascular invasion. 
Among these, lymph node status is an independent prognostic factor because 
the number of lymph nodes involved is positively associated with clinical 
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outcome. Tumour size also predicts for poor survival independent of axillary 
lymph node status. Moreover, numerous studies have found that tumor grade 
is another important prognostic factor, with correlation between poor survival 
and poor differentiation of tumours. Apart from the prognostic value of these 
conventional clinicopathological factors, a number of studies have reported 
that baseline tumor gene signatures could be a potential prognostic marker in 
breast cancer. The 21-gene Recurrence Score (Oncotype DX) and Netherlands 
70-gene signature (MamaPrint) have been commercially available for clinical 
use (13-15). Patients with a low expression of 70-gene signature show good 
clinical outcome. Incorporating the 70-gene signature to clinical risk 
prediction model improves risk predictions of early stage node-negative breast 
cancer patients (16). 
2.2 Tumor Microenvironment 
The theory of“seed and soil theory”was initially proposed by Paget in the 
1880s (17). Recent evidence on breast, skin and gut tumors (18, 19) has been 
evolving the concept that tumor growth is not only determined by the tumor 
cells alone, but also by the microenvironment. Tumor cells make use of 
nutrition, oxygen and other supporting factors in the microenvironment to 
grow and metastasize. Tumor microenvironment is the active interaction 
between stromal tissue and extracellular matrix (ECM)  (17).  
2.2.1 Stromal Tissue 
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Stromal tissue plays a crucial role as a supportive and connective tissue, which 
consists of many different types of cells. The main components of stromal 
tissue include fibroblasts, myofibroblasts, infiltrating macrophages and 
lymphoctyes, vascular as well as lymphovascular endothelial cells. Increasing 
number of studies has shown that stromal tissue regulates the development and 
progression of cancer. The cells of the stromal tissue actively interact with 
surrounding malignant cells (20). For example, fibroblasts are able to secrete 
factors which target the cancer cells in both a paracrine and autocrine manner. 
These networks formed by stromal and cancer cells result in a more aggressive 
phenotype of cancer.  
2.2.2 Cancer Associated Fibroblasts  
Cancer-associated fibroblasts (CAF) are fibroblasts which are present in the 
tumor microenvironment (21-23). Many kinds of cells are considered as the 
major sources of CAF, such as normal fibroblasts, pericytes, fibrocytes, 
mesenchymal stem cells and smooth muscle cells. Moreover, both epithelial-
mesenchymal transition and endothelial-mesenchymal transition are additional 
sources for generation of CAF. In contrast to its counterpart normal fibroblasts 
which mainly provide the component of connective tissue to support tissue 
structural integrity, CAF play a crucial role in the deposition of ECM by 
synthesizing ECM proteins such as collagen, laminin and fibronectin. CAF 
also secrete soluble growth factors to promote tumor growth, such as 
transforming growth factor-β, epidermal growth factor and hepatocyte growth 
factor (24).  
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2.2.3 Extracellular Matrix  
The ECM is the non-cellular component present within all tissues and organs 
and is mainly secreted by CAF and infiltrating tumor cells. The ECM is 
composed of water, proteins and polysaccharides. ECM proteins comprise 
almost 300 proteins, including 43 collagen subunits, three dozen or so 
proteoglycans, and around 200 glycoproteins (25). Among ECM glycoproteins, 
22 glycoproteins are major known ECM proteins, such as laminins, 
fibronectins, thrombospondins, tenascins and secreted acidic cysteine-rich 
glycoproteins SPARC and SPARC-like. The structures of these glycoproteins 
are well known and exemplify the typical multiple repeating domain structure 
and extended multimeric forms of ECM proteins (25). 
The ECM serves as a structural scaffold and provides the support necessary to 
maintain tissue integrity and sustainability. However, the ECM is much more 
than simply a structural framework as it can affect the fate of tumor cells via 
multiple mechanisms. For example, the matrix binds growth factors and 
cytokines to affect stability and bioavailability of these factors (26). 
Furthermore, the ECM provides adhesive surface to cells inducing survival 
signalling via integrins and activation of focal adhesion kinase (FAK). ECM 
proteins are moreover the key molecules that mediate mechanical forces 
within tissues and this tension can dictate how the cells respond to growth 
factors and cytokines. Importantly, the combination of these effects exerted by 
the ECM provides an important context of cell regulation in tumor. In addition, 
the ECM remodelling is one of the early steps during the formation of the 
tumor microenvironment. During this process, the structure of the ECM is 
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digested by matrix metalloproteinases (MMPs) (27). MMPs are able to 
hydrolyse protein macromolecules. MMPs-regulated digestion of the ECM 
allows the entry of cancer cells into the stromal tissue and migration of 
endothelial cells into the matrix which results in tumor cell invasion and 
neovascularization.      
2.3 Integrin Pathway 
Integrin was originally defined as a group of transmembrane proteins which 
function as a link for signal between the cytoskeleton and the ECM (28). It is 
made up of 18 α-subunits and 8 β-subunits, which can form 24 known distinct 
αβ-heterodimers depending on cell type and cellular function. The β1 integrin 
subfamily is composed of 12 members as defined by the participating α 
subunit (α1–α12), is widely expressed, and constitutes a major class of 
integrins that mediate cell interactions with matrix proteins. Each integrin 
subunit is a protein spanning over the membrane, and contains extracellular, 
transmembrane and intracellular domain. ECM proteins share a common tri-
peptide cell binding site, Arg-Gly-Asp, which is the motif to which the 
majority of integrin bind. This binding further leads to adhesive interactions 
between integrin and ECM (29). Therefore, some integrins can function as 
receptors for more than one ECM protein (30). There is often more than one 
integrin receptor for a given ECM protein (31).  
In cancer cells, by cooperating with growth factor signalling, integrins play an 
important role in regulating  adhesion to the ECM, migration, survival and 
proliferation of cancer cells (27). Specifically, the role of integrins in 
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regulating migration has been extensively explored. Following binding of 
ECM ligands to the extracellular integrin domain, integrins form clusters into 
focal contacts. Focal contacts are the gathering place for many distinct actin-
associated proteins, which link the integrin signal to the cytoskeleton (32). The 
integrins-activated intracellular signalling are dependent on the composition of 
ECM which integrins bind to. Subsequently, integrins activate multiple 
intracellular signalling pathways which regulate cytoskeletal organization, 
force generation and survival (27). These pathways typically involve 
dephosphorylation of FAK, activation of small guanosine triphosphatases 
(GTPases) and further activation of downstream effectors (Figure 2.1). 
 
Figure 2.1. Cooperation between integrin and growth factor signalling Signalling 
activated by either ECM ligation to integrins or growth factor binding to RTKs may 
activate common downstream pathways resulting in enhanced signalling overall 
compared with the activation of either receptor alone. This signalling commonly 
converges on Src family kinases (SFKs) and Ras family proteins and further activates 
downstream effectors to enhance survival and cell migration. ECM, extracellular 
matrix; EGF, epidermal growth factor; FAK, focal adhesion kinase; RTK, receptor 
tyrosine kinase. Adapted from [Ref (2)] 
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2.4 Mevalonate Pathway  
The mevalonate pathway is an important cellular metabolic pathway to 
regulate cholesterol synthesis and protein prenylation (Figure 2.2). The first 
committed step of the mevalonate pathway involves HMG-CoA reductase. 
HMG-CoA reductase catalyzes HMG-CoA conversion to mevalonate, which 
is further metabolized to isopentenyl pyrophosphate (IPP) and dimethylallyl 
pyrophosphate (DMAPP). DMAPP is subsequently catalyzed by farnesyl 
pyrophosphate (FPP) synthase and geranylgeranyl pyrophosphate (GGPP) 
synthase to form FPP and GGPP respectively. Both FPP and GGPP serve as 
adjuncts for a post-translational modification at the C-terminus of a variety of 
important cellular proteins, which is referred to as protein prenylation (33). 
Protein prenylation creates a lipidated hydrophobic domain and plays a role in 
membrane attachment or protein-protein interactions, which in most cases is 
an essential requirement for the biologic function of proteins. Prenylation 
occurs in many members of the Ras and Rho family of small GTPases (34, 35).  
2.4.1 Statins  
Statins are a family of common cholesterol-lowering drug prescribed to 
control hypercholesterolemia. Statins are classified as lipophilic (atorvastatin, 
simvastatin, lovastatin, fluvastatin, and cerivastatin) and hydrophilic 
(pravastatin and rosuvastatin) statins. They are small-molecule inhibitors of 
HMG-CoA reductase. Therefore, statins inhibit mevalonate pathway by 
inhibiting HMG-CoA reductase and subsequently decrease levels of 
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mevalonate and downstream metabolic products, such as FPP and GGPP to 
inhibit cholesterol and protein prenylation  (33).  
Through inhibition of prenylation of Ras and Rho proteins, statins may 
suppress extensive downstream signalling pathways of both Ras and Rho, 
which are commonly abrogated in many types of cancer. The pathways 
inhibited by statins control cell cycle progression, cell survival and migration, 




Figure 2.2  Mevalonate metabolism. The mevalonate pathway produces isoprenoid 
precursor units, which are required for the biosynthesis of a variety of important 
molecules that contribute to diverse cellular functions, such as cholesterol synthesis 
and protein prenylation (e.g., Ras). Statins are drugs that inhibit mevalonate 




2.4.2 Ras Downstream Pathways 
The RAS family of GTPases comprises HRAS, NRAS, and KRAS. It has 
important roles in multiple fundamental cellular functions of regulating 
apoptosis, migration, proliferation and differentiation. RAS proteins are 
molecular switches that cycle between GTP- and GDP-bound forms; GTP-
bound forms are active whereas GDP-bound forms are inactive (38). Active 
mutations in genes of RAS family are among the most common genetic 
aberrations in human cancers (39). Upon activation, RAS subsequently 
stimulates a numbers of downstream signalling pathways.  
2.4.2.1  RAF/MEK/ERK (MAPK) pathway 
The first known RAS downstream effector cascades are the RAF/MEK/ERK 
pathway (40-42) which is an essential mitogenic signalling pathway through 
tyrosine kinase receptors. As shown in Figure 2.3, the serine/threonine kinase 
RAF family of protein (A-Raf, B-Raf and C-Raf) is one of the most well-
established downstream effectors of Ras. GTP-bound RAS directly binds to 
and activates RAF proteins and thus induces translocation of protein to plasma 
membrane. Upon translocating to the cell membrane, Raf protein is 
phosphorylated/activated by different protein kinases. RAF activation further 
phosphorylates downstream effectors, mitogen-activated protein kinase 
kinases 1 and 2 (MEK1 and MEK2), which subsequently phosphorylate 
mitogen-activated protein kinases (MAPKs)/extracellular signal-regulated 
kinases 1 and 2 (ERK1 and ERK2). ERK1/2 activate their substrate 
transcription factors, such as C-Jun and AP1, to promote the expression of cell 
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cycle proteins including D-type cyclins, which enables the cell cycle 
progression from G1 to S phase. Mutations of the components of this pathway 
are relatively rare in breast cancer with only about 3% of tumors harboring B-
Raf mutations. 
2.4.2.2 PI3K/Akt/mTOR pathway 
The second well-known RAS downstream effector is phosphoinositide 3-
kinases (PI3Ks), which mediates RAS-regulated cell proliferation and survival 
(43). As shown in Figure 2.3, PI3K pathway signalling may be activated 
through cell surface receptors, such as G protein-coupled receptors and 
receptor tyrosine kinases (RTKs). RTKs include epidermal growth factor 
receptor, Her2, insulin like growth factor-1 receptor. The activation of PI3K 
by generating PIP3 drives multiple downstream pathways that regulate a wide 
range of cellular responses including control of tumor development and 
progression (43). In contrast, the tumor suppressor phosphatase and 
tensinhomolog (PTEN) dephosphorylates phosphatidylinositol-3,4,5-
trisphosphate (PIP3) to phosphatidylinositol-4,5-bisphosphate (PIP2) and 
therefore negatively regulates PI3K signalling. The serine/threonine kinase 
Akt is one of the major direct PI3K effectors in cancers. Akt subsequently 
activates one of its main effectors, the mammalian target of rapamycin 
(mTOR), which contains mTOR complex 1 (mTORC1), leading to increased 
activity of p70S6 kinase (43, 44). Moreover, p70S6K directly target S6 
ribosomal protein, whose phosphorylation promotes the translation of mRNA 
that has ologopyrimidine tracts in the 5’ untranslated region. p70S6 kinase 
also activates translational repressor 4E-BP1, a protein that plays a key 
17 
 
regulatory role on the inhibition of cap-dependent mRNA translation by 
negatively controlling the function of elF4E. PIK3CA mutation is common in 
breast cancer (45). 
    In the context of  breast cancer, the downstream pathways of Ras, such as 
MAPK and PI3K/Akt/mTOR signalling pathways, are commonly activated 
and play important roles in regulating breast cancer cell growth, survival, 












      
Figure 2.3  MAPK and the PI3K pathways  Growth factors stimulation results in 
receptor tyrosine kinases (RTKs) phosphorylation which stimulates RAS activation. 
In their active form, RAS-GTPase proteins bind to and recruit RAF to the plasma 
membrane. RAF then phosphorylates and activates MAPK kinases/extracellular-
signal-regulated kinases (MEK), which in turn phosphorylates and activates ERK. 
Activation of ERK regulates both cytosolic proteins and transcription factors 
involved in cell cycle progression and tumor survival. Following activation by RTKs 
or RAS, PI3K phosphorylates PIP
2
 to generate PIP
3
 which activates AKT. The PI3K 





. AKT controls cell growth, survival and metabolism 
through phosphorylation of a number of key substrates. The signal proceeding 
through the tuberous sclerosis complex (TSC), mammalian target of rapamycin 
(mTOR) and S6 ribosomal proteins (S6K) affects primarily protein synthesis. GEFs: 






2.5 Neoadjuvant Treatment 
2.5.1 Neoadjuvant Chemotherapy and Chemotherapy Drugs 
Neoadjuvant chemotherapy refers to the administration of chemotherapy prior 
to definitive surgery. Currently, neoadjuvant chemotherapy has become a 
common strategy for the management of operable and inoperable locally 
advanced breast cancer. Neoadjuvant chemotherapy targets micrometastases 
and downsizes the tumor to improve the chance of breast conservation. 
Response to neoadjuavant chemotherapy has become an additional prognostic 
tool, where patients with complete pathological responses have been shown to 
have an improved survival (47).  Moreover, neoadjuvant chemotherapy is an 
effective in vivo model to study the efficacy of novel agents or combined 
therapeutic strategies against breast cancer, and provides opportunity for 
repeated sampling of the primary breast tumor for the study of prognostic and 
predictive biomarkers. 
2.5.1.1 Docetaxel 
Docetaxel belongs to the family of taxane drug class with function of anti-
mitosis of cells. Docetaxel is clinically well-established for treatment of 
locally advanced or metastatic breast cancer and other common solid tumors. 
Depending on tumor type and stages, docetaxel can be used alone or in 
combination with other chemotherapeutic agents. Its mechanism of action is to 
maintain microtubulin assembly and stabilize the polymers to suppress 
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microtubule dynamics (48). This interference of microtubules deregulates both 
cell cycle progression and signalling pathways controlling apoptosis (49).  
2.5.1.2 Doxorubicin  
Doxorubicin is a common anthracycline drug used for treatment of a number 
of tumors, including hematologic malignancies, carcinoma and sarcoma. It is 
often used in combination with other chemotherapy drugs. By binding to DNA 
associated enzymes, such as topoisomerase enzymes II, doxorubicin 
intercalates the base pairs of the DNA’s double helix and thus inhibits 
relaxation of supercoils in DNA for transcription (50) and further keeps the 
DNA double helix from being resealed and thereby stops the process of 
replication (51). It may also increase free radical production which, in turn, 
enhances cell cytotoxicity  (51).  
2.5.2 Window-of-Opportunity Trial 
The high number of new molecular entities (e.g., kinase inhibitors and 
monoclonal antibodies) in clinical investigation raises the question if 
alternative clinical trials design could help to promote the approval rate of 
these new agents. Window-of-opportunity trial is a clinical trial design which 
offers a valuable alternative to detect the biological activity of promising new 
drugs. While waiting to undergo definitive cancer surgery, newly diagnosed 
patients are treated with the drug of interest for a short period of time, 
typically 2-4 weeks, to determine whether the agent has the desired 
pharmacodynamic or molecular effect. The aim is to obtain knowledge about 
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biological activity of the new agent or combination in a disease state that is not 
disturbed by prior anti-cancer therapy (52).  
2.6 ECM/integrin Signalling and Chemotherapy Resistance 
As discussed in the previous section, ligation of ECM with integrin receptors 
on cancer cells induces a variety of intracellular signals and regulates several 
responses including migration, survival and proliferation. Recent studies have 
also shown, under the exposure of chemotherapy drugs, that ECM/integrin 
signalling could protect cancer cells from cytotoxic effects of chemotherapy. 
Most notably, the implication of ECM/integrin interactions in modulating 
chemotherapy resistance seems to be a general phenomenon and occurs in 
both solid tumors and haematological malignancies in response to different 
classes of chemotherapy drugs (1, 53, 54). In solid tumors, the effect is mainly 
mediated via integrin β1 among which α2β1, α3β1, α6β1 and αvβ1 are the 
most expressed on cancer cells. Furthermore, the protective effect of β1 
integrins is mediated through activation of the PI3k/AKT pathway, which 
inhibited drug-induced cell cycle arrest and caspase-3 activation (55-57). The 
role of PI3K/AKT in ECM/integrin-medicated chemotherapy resistance is 




Figure 2.4 Role of PI3K/AKT in ECM/integrin-mediated chemotherapy 
resistance  ECM/Integrin interactions lead to the activation of PI3K/AKT which can 




CHAPTER 3. IDENTIFICATION OF PROGNOSTIC AND 
PREDICTIVE ROLE OF CAF/ECM AND INTEGRIN PROTEINS 
IN BREAST CANCER 
3.1 Introduction 
Breast cancer can be classified according to their stromal gene profile, which 
provides prognostic information independent of conventional tumor features, 
such as ER or Her2 status (58). Stromal gene signatures may also predict 
resistance to chemotherapy such as anthracyclines in breast cancer (59). 
Previously, using iTRAQ based LC-MS/MS, we found three ECM proteins, 
THBS1, TNC and FN, to be significantly up-regulated after 1 cycle of 
chemotherapy in tumors that were intrinsically resistant to doxorubicin or 
docetaxel (unpublished data). Moreover, another ECM protein, SPARC 
(secreted protein, acidic and rich in cysteine), has drawn increasing attention 
as its expression is increased in breast cancer compared with healthy breast 
tissue (60). Several studies, which have evaluated the prognostic relevance of 
SPARC expression in breast cancer tissue, show SPARC expression is 
associated with promotion of tumor growth and metastasis, more aggressive 
tumor types and worse prognosis (60-62). Furthermore, ECM proteins are 
mainly synthesized and secreted by CAF and smooth muscle actin-alpha (α-
SMA) is a typical CAF biomarker. Therefore, in this thesis, we selected 
THBS1, TNC, FN, SPARC and α-SMA, as representative ECM/CAF proteins 
to study the role of tumor stroma in regulating response to chemotherapy. 
These five major known CAF/ECM proteins have been reported to be 
associated with increased invasiveness (63-65), treatment response (62, 66) 
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and poor prognosis (61, 67, 68) of breast cancer. Their functional roles in 
breast cancer progression are briefly summarized in Table 3.1. 
Table 3.1 Functional roles of 5 selected CAF/ECM proteins in breast cancer 
progression 
THBS1, TNC, FN and SPARC are also known as ECM proteins, many of 
which are ligands for integrins on tumor cell surface. It has been long 
proposed that there is an association between the expression of integrins and 
the metastatic capability of breast cancer. Although no uniform integrin 
expression pattern can be ascribed to all subtypes of breast cancer, aggressive 
breast cancer do exhibit increased expression of certain integrins, including 
integrin subunit α6 (74, 75), α9 (76) and β1(74, 76). Both subunits α6 and α9 
are partners of β1 subunit in breast cancer (76). Importantly, these subunits are 
key components of the integrin receptors for ECM proteins THBS1 (α6 and 
β1), TNC (α9 and β1), FN (β1) and SPARC (α9 and β1) (77). Adhesion of the 
ECM to the integrins on the cancer cell surface permits growth factor-
dependent activation of Ras, which through PI3K/Akt/mTOR pathway 
promotes G1/S transition (56). In addition, the PI3K/Akt/mTOR pathway is 
one of the most frequently over-activated pathways in breast cancer with 
CAF/ECM Functional roles in breast cancer 
THBS1 Metastasis-promoting (69, 70) 
TNC Metastasis-promoting (71, 72) 
FN Structural ECM (scaffold for angiogenesis, tumorigenesis and 
assembly of other matrix proteins); metastasis-promoting (26) 
SPARC Metastasis-promoting (73) 
α-SMA A typical biomarker for myofibroblasts and CAF (24) 
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chemotherapy resistance (78). Several studies have shown the role of ECM in 
tumor cell protection against chemotherapy via integrin β1 through activating 
PI3K signaling pathway in lymphoma cells (79, 80). However, the role of 
ECM/integrin in protecting breast cancer cells against chemotherapy remains 
elusive. 
Thus, one aim of the first part of this thesis was to determine the changes in a 
panel of CAF/ECM (THBS1, TNC, FN, α-SMA and SPARC) and integrin 
subunit (α6, α9 and β1) proteins, following neoadjuvant chemotherapy in 
breast cancer patients using IHC staining. Based on the clinical findings, 
THBS1 and TNC, which were identified to be more relevant to 
chemoresistance in the clinical studies, were chosen for functional studies 
using breast cancer cell lines to further explore their underlying mechanisms 
to regulate chemotherapy resistance. In clinical specimens, we found 
CAF/ECM and integrin protein expression to correlate with poor survival, 
intrinsic chemotherapy response and pathological lymph node involvement at 
surgery. In functional studies, we found both THBS1 and TNC to protect 
MCF-7 cells proliferation against docetaxel through activating integrin 
β1/mTOR pathway.  
3.2 Patients, Materials and Methods 
The workflow of clinical and functional studies is summarized in Figure 3.1, 
and includes two neoadjuvant chemotherapy clinical trials (a primary and an 
independent validation cohort), serial tumor biopsies taken from the patient 
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enrolled into the clinical trials, biomarkers detected by IHC staining, 
exogenous THBS1 and TNC treatment on MCF-7 cells and analysis of 






Figure 3.1  Workflow of the clinical and functional studies for CAF/ECM 
project  For clinical studies, tumor samples were collected from patients enrolled into 
two neoadjuvant chemotherapy clinical trials, a primary cohort (n=100) and an 
independent validation cohort (n=31), respectively. Tissue microarray was 
constructed with tumor biopsies taken from the primary cohort. Apart from 
immunohistochemistry (IHC) staining on tissue microarray (TMA) sections of the 
primary cohort, all IHC staining was performed on full sections, including 30 cases 
from baseline biopsies of the primary cohort which contained both tumor cells and 
adjacent normal tissues in the full sections. The changes in THBS1, TNC, FN, α-
SMA, SPARC, integrin α6, α9 and β1 following neoadjuvant chemotherapy was 
detected by IHC staining. The changes in THBS1, TNC and integrin α6 were further 
confirmed by IHC staining using the validation cohort. For functional studies, MCF-7 
cells were treated with docetaxel with or without either recombinant THBS1 or TNC. 
MTS assay and Western blot analyses to detect changes in cell viability, proliferation 




3.2.1 Patients and Clinical Trials 
3.2.1.1 A phase II Neoadjuvant Study with Doxorubicin and Docetaxel 
in Breast Cancer Patients (Primary Cohort)  
100 patients with histologically or cytologically proven, treatment-naïve, 
locally advanced or metastatic breast cancer were recruited into a prospective 
phase II study and randomized to one of two alternating sequences of 





 every 3 weeks for six cycles (A-T-A-T-A-T, n=49; T-
A-T-A-T-A, n=51). Pre- and post-treatment tumor biopsies after the first and 
second cycle of chemotherapy were collected.  
3.2.1.2 A phase II Neoadjuvant Study with Docetaxel in Breast Cancer 
Patients (Validation Cohort)  
31 breast cancer patients were recruited into a phase II clinical trial and treated 
with four cycles of three-weekly neoadjuvant single-agent docetaxel. Pre- and 
post-treatment tumor biopsies after the first and fourth cycle of chemotherapy 
were obtained. All trials were conducted at the National University Hospital of 
Singapore and were approved by the ethics review board of the institution. 
Written informed consent was obtained from all participants.  
3.2.2 Definition of Treatment Outcomes  
Changes in tumor size were assessed at every cycle using the World Health 
Organization (WHO) criteria (81). Patients were classified as having 
intrinsically sensitive tumors to the chemotherapy drug that they received in 
the first cycle if they achieved ≥25% reduction in tumor dimensions after the 
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first cycle; those with <25% reduction were defined as having intrinsically 
resistant tumors to the drug received. Progression-free survival (PFS) and 
overall survival (OS) were defined as the time between the date of 
randomization and the first documented evidence of progression (PFS) or 
death (OS) respectively, or the last follow-up whichever came first.  
3.2.3 Materials and Methods 
3.2.3.1 Tissue Processing of Tumor Biopsies 
Tumor biopsies were fixed in 10% neutral buffered formalin for 24 hours, 
followed by gradual dehydration with 50, 70, 95 and 100% ethanol, clearing 
with xylene and infiltrating with paraffin wax using tissue processor (Shandon 
Citadel 1000, ThermoScientific). Processed tumor biopsies were finally 
embedded in paraffin for sectioning. 
3.2.3.2 Tissue Microarray (TMA) Construction for Tumor Biopsies from 
the Primary Cohort 
A total of 3 serial tumor core biopsies were collected from subjects enrolled 
into the primary cohort; before chemotherapy, and 3 weeks after cycle 1 and 2 
chemotherapy respectively. Each tissue block was examined using H&E 
staining to confirm the presence of invasive cancer, and a morphologically 
representative area was marked. A core from the marked area of donor tissue 
block was punched using a 1.5 mm diameter needle and then inserted into a 
recipient paraffin block using a tissue arrayer ATA-100 (Chemicon, USA).  
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3.2.3.3 Immunohistochemistry (IHC) Staining 
Consecutive sections of 4µm thickness were cut from the TMAs of the 
primary cohort for IHC analysis. In addition, full sections from 30 cases of 
baseline breast tumor specimens from the primary cohort containing adjacent 
normal tissue, and from the biopsies of all patients from the validation cohort 
were sectioned. Antigen retrieval was performed with either 10mM pH 6.0 
citrate buffer or proteinase K, following by visualizing IHC signals with 
EnVision+ System kit (Dako, Norway) according to the instructions of the 
manufacturers. Briefly, peroxidase block was applied to quench endogenous 
peroxidase activity for 5 minutes and specimens were then incubated with 
primary antibodies at optimal dilutions at 4°C overnight, respectively. 
Specimens were further incubated with horseradish peroxidase labelled 
polymer secondary antibodies for 30 minutes. Staining was visualized by a 1 
to 5-minute incubation with 3,3'-diaminobenzidine (DAB)+ substrate-
chromogen which generated a brown-colored precipitate at the primary site of 
antigen. The slides were then counter-stained with hematoxylin, following by 
routine dehydration with ethanol at gradually increasing concentrations and 
clearance with histoclear (National Diagnostics, Atlanta, GA). Negative 
controls were performed simultaneously without the incubation with the 
primary antibody and other procedures were unchanged. IHC staining was 
observed under normal light microscope (BH, Olympus, Japan). Antibodies, 
dilutions and manufacturers for IHC staining were listed in Table 3.2. 
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3.2.3.4 Scoring of IHC Expression of Proteins 
 The IHC expression of proteins was independently scored by two pathologists 
(Wang Tingting and Supriya Srivastava) and consensus was reached for the 
cases with discrepancy. Different scoring criteria were applied for individual 
biomarkers according to their differential immunostaining patterns. The 
immunostaining intensity of THBS1 (82), TNC (83), FN (83)  and SPARC 
was scored as 0 to 3 for negative, mild, moderate and strong staining 
respectively. Scoring for α-SMA was determined by assessing percentage of 
positive staining (84). The immunostaining of integrin proteins α6, α9 and β1 
(85, 86) was graded according to H-score system, which considers both 
staining intensity and positive staining extent. Staining intensity was scored as 
described above. Staining extent referred to the estimated percentage of 
positive staining cells in the whole cancer compartment 
IHC score = staining intensity × staining extent 
The range of H-score was from 0 to 300. To determine the cut-off scores for 
high or low immunoreactivity, receiver-operating characteristic curve with 
SPSS statistical software was applied. The cut-off scores for determining high 
or low immunoreactivity of each biomarker were shown in Table 3.2.  
Changes in CAF/ECM proteins expression from baseline after chemotherapy 
were calculated as follows: change from baseline (%) = 100% × (mean 




Table 3.2 Dilutions and manufacturers for antibodies and cut-offs for 
immunohistochemistry staining of CAF/ECM/integrin project 
3.2.3.5 Reagents and Cell Culture 
Docetaxel was purchased from Sigma-Aldrich Co (St. Louis, MO, USA) and 
dissolved in dimethyl sulfoxide (DMSO) which was used as vehicle control. 
Purified human THBS1 and TNC protein were purchased from EMD 
Millipore Corporation (CA, USA). Charcoal stripped fetal bovine serum (CS-
FBS) was obtained from Nacalai Tesque (Kyoto, Japan). Human breast cancer 
cell line MCF-7 (ER+) was obtained from American Type Culture Collection 
(ATCC, Manassas, VA, USA) and maintained in high glucose Dulbecco’s 




Cut-offs for low vs high 
expression 
THBS1 1:200, R&D System Positive staining ≤1 vs >1 
TNC 1:1000, Abcam Positive staining ≤2 vs >2 
FN 1:300, R&D System Positive staining ≤1 vs >1 
SPARC 1:150, R&D System Positive staining ≤1 vs >1 











Positive staining <110 vs 
≥110a 
Integrin α9 1:100, Sigma-Aldrich Positive staining <5 vs ≥5
a
 




 Determined by receiver-operating characteristic curve in SPSS software; b Refer to 
Section 3.2.3.9 for the description of combined CAF/ECM; NA: not applicable 
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with 10% fetal bovine serum (FBS) and 1X penicillin-streptomycin 
(Invitrogen, Carlsbad, CA) at 37°C in a humidified atmosphere with 5% CO2.   
3.2.3.6 Cell Treatment with Exogenous THBS1 or TNC 
Our clinical findings showed that THBS1 and TNC were more associated with 
chemotherapy resistance than the other three CAF/ECM proteins, FN, SPARC 
and α-SMA. Therefore, we went on to further investigate the underlying 
mechanisms by which THBS1 and TNC regulated chemotherapy resistance by 
functional studies. To explore the protective effects of exogenous THBS1 or 
TNC on MCF-7 cells, 3000 cells per well in 96-well plate were grown in 
DMEM containing 10% FBS overnight and then replaced with DMEM 
containing 5% CS-FBS for 48 hours. THBS1 or TNC at indicated 
concentrations (0, 0.01, 0.1, 1 and 5µg/ml) were then added into the cell 
culture media respectively and maintained for another 48 hours, with or 
without treatment with 5nM docetaxel. DMSO was used as vehicle control for 
docetaxel. All experiments were performed in triplicates.  Similar experiments 
were applied to cells seeded in 10cm dish for Western blot analysis. 
3.2.3.7 Cell Viability Assay 
Cell viability assays were carried out for cells treated in Section 3.2.3.6 by 
mixing with 20μl reagent containing a tetrazolium compound [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H 
tetrazolium, MTS] (Promega, Madison, WI). The mixture was incubated at 
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37°C for 1 hour and the absorbance at 490nm was determined using a 96-well 
plate reader (Tecan, Männedorf, Switzerland). 
3.2.3.8 Western Blots Analyses 
Western blot analyses were carried out with cells treated in Section 3.2.3.6. 
After treatment, cell pellets were collected and subsequently lysed in lysis 
buffer (1% Triton X-100, 1 mM EDTA, 50 mM Tris-HCL pH8, 50 mM NaCl, 
0.1% sodium deoxycholate, 1x Protease inhibitor and 1X Phosphatase 
inhibitor). After 30 minutes, cell debris was removed by centrifugation at 
13,000 rpm for 10 minutes at 4°C. Protein concentration was determined using 
Pierce BCA protein assay kit (Thermo Fisher Scientific, Rockford, IL).  
Proteins were denatured in sample buffer by boiling for 5 minutes at 95°C. 
15g of protein per well was separated by SDS polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride 
(PVDF) membranes (Millipore, Billerica, MA). The membranes were blocked 
with 5% non-fat milk in TBS containing 0.2% Tween 20, and incubated with 
different primary antibodies overnight at 4°C. The membranes were then 
washed with TBS containing 0.2% Tween 20 and incubated with specific 
secondary antibodies conjugated with horseradish peroxidase (Cell Signaling 
Technology, Billerica, MA) for 1 hour at room temperature. Proteins were 
detected by enhanced chemiluminescent immunodetection system (GE 
Healthcare Life Science, Little Chalfont, UK). Antibodies used for Western 
blot analyses were summarized in Table 3.3. All antibodies were purchased 
from Cell Signaling Technology (Billerica, MA) and working concentration 




Table 3.3 Antibodies used for Western blots analyses of CAF/ECM/integrin 
project 
Antibodies MW (kDa) 
C-myc 57-65 
Cyclin D1 36 
p27 27 
p70S6K 70,85 
p-p70S6K (Thr389) 70,85 
S6 ribosomal protein (S6RP) 32 
p-S6RP (Ser235/236) 32 
Integrin β1 115, 135 
β-actin 45 
MW: molecular weight 
 
 
3.2.3.9 Survival Model Construction of Proteins Expressed by 
CAF/ECM 
To study the combined effect of CAF/ECM proteins on PFS and OS, patients 
with at least 3 baseline CAF/ECM proteins scores (n=78) in the primary 
cohort were selected to construct a CAF/ECM score model. The expression 
levels for individual CAF/ECM protein were assigned as three levels; high 
expression, low expression and missing. Each individual CAF/ECM protein 
was modeled separately using a Cox regression model adjusted for age, tumor 
grade, metastasis, tumor size, pathological lymph node involvement, ER, PR 
and Her2 status, in order to generate an adjusted effect of the CAF/ECM 
protein on the outcome of interest. From these models the regression 
coefficients for each protein – high, low and missing was extracted and 
subsequently used to create a CAF/ECM combined score by summing up all 
coefficients for each patient. Each patient was then categorized into a 
combined high and low expression CAF/ECM group based on the median 
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value of the summed coefficients. This score was entered into a final 
multivariate Cox regression testing the independent effect of high versus low 
CAF/ECM combined score. 
3.2.3.10 Statistical Analysis 
Statistical analysis methods used in this thesis were summarized in Table 3.4. 
Univariate and multivariate Cox regression models were carried out with PFS 
or OS as the end point. Multivariate Cox regression models were adjusted for 
age, tumor grade, metastasis, tumor size, pathological lymph node 
involvement, ER, PR and Her2 status. For this purpose, we entered all 
variables which were associated with survival on univariate analysis (cut off 
p<0.1), into a multivariate Cox model. Backward stepwise selection models 
were used to remove variables that did not contribute significantly to the 
outcome. The final model only comprised variables that were significantly 
associated with the outcome. In this thesis, p value for each biomarker in 
clinical samples was not corrected for multiple testing. We did an exploratory 
data analysis, which is an approach to summarize main characteristics beyond 
hypothesis testing task. Therefore if we do not do multiple testing, we do not 
discard markers that may be significant but will be excluded because of small 
sample size. Exploratory analysis will then have to be followed by validation 
in a larger sample set. All statistical analyses were carried out using the IBM 
SPSS package (version 19.0 for Windows, IBM SPSS Inc., USA). The 
significance was set at the 5% level. 
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Table 3.4 Methods used for statistical analysis of CAF/ECM/integrin project 
Statistical methods  Purposes 
Mann-Whitney U  
Correlation between baseline CAF/ECM protein 




Changes in CAF/ECM and integrin protein 
expression from baseline following neoadjuvant 
chemotherapy 
Friedman test 




Correlations amongst CAF/ECM proteins  
Kaplan-Meier  Survival analysis  
Log-rank test  
Difference between high  and low CAF/ECM and 




Independency of prognostic value of CAF/ECM 
and integrin proteins 
One-way ANOVA 
Protective effects of exogenous THBS1 and TNC 
against docetaxel  
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3.3 Results  
ECM proteins are much more than ligands for integrins as they can regulate 
the progression of tumor via multiple mechanisms, such as affecting 
availability of growth factor, mediating mechanical forces within tissues, and 
ECM remodelling (26). CAF/ECM proteins are mainly expressed by CAF and 
localized in the region of tumor stroma, whereas integrin proteins are mainly 
expressed by cancer cells (Figure 3.2). Following neoadjuvant chemotherapy, 
changes in CAF/ECM proteins represent the tumor stroma-based response to 
chemotherapy, while changes in integrin proteins reflect cancer cell-based 
response to chemotherapy. 
 
Figure 3.2  Diagram of comparison between CAF/ECM and integrin proteins  




Therefore, in this Section, the results for the prognostic and predictive values 
of CAF/ECM proteins are separated from that of integrin proteins to highlight 
the different responses of tumor stroma and cancer cells to chemotherapy. 
Following clinical findings, functional data for the underlying mechanisms by 
which THBS1 and TNC regulated chemotherapy resistance were presented. 
Schema for the workflow of the results of the first part of the thesis is shown 





Figure 3.3 Schema of the workflow for the Result Section of CAF/ECM/integrin 




3.3.1 Prognostic and Predictive Values of CAF/ECM Proteins in Breast 
Cancer 
3.3.1.1 Clinicopathological Characteristics of the Primary Cohort             
The median age for the primary cohort was 50 years (range 26-68). The 
median follow-up time was 53.8 months (range 1.4-88.7). Mean PFS and OS 
were 45.3 [95% CI 38.4-52.3] and 59.4 [95% CI 53.1-65.7] months, 
respectively (Table 3.5).  
Table 3.5 Clinicopathological characteristics of the primary cohort  
  (n, %)  
Age   
<50 53 (53) 
>=50 47 (47) 
Ethnicity 
 Chinese 65 (65) 
Malay & others 35 (35) 
Tumour grade 
 1 10 (10)  
2 49 (49)  
3 41 (41)  
T4 stage 
 No 26 (26) 
Yes 74 (74) 
Metastasis 
 No 69 (69) 
Yes 31 (31) 
Treatment arm 
 A-T-A-T-A-T 49 (49) 
T-A-T-A-T-A 51 (51) 
25% tumour reduction at cycle 1 
 <25% 43 (43) 
≥25% 57 (57) 
Pathological lymph node involvement 
a
  
No  31 (41) 
Yes 44 (59) 
a: 75 patients underwent surgery  
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3.3.1.2 Expression of CAF/ECM Proteins in Tumor versus Adjacent 
Normal Tissue 
In the primary cohort, some baseline tumor core biopsies contained adjacent 
normal tissue which allowed us to compare the differential expression of 
CAF/ECM proteins between tumor and its adjacent normal tissue (n=30). In 
the adjacent normal tissue, CAF/ECM proteins immunostaining was detected 
on the blood vessels (TNC, FN and α-SMA), basement membrane (TNC), 
myoepithelial (α-SMA) and luminal (SPARC) cells of mammary glands 
respectively (Figure 3.4a, c, e, g, i). In contrast, weak to strong expression of 
the 5 CAF/ECM proteins was predominately found in cancer-associated 
stroma, apart from concordant immunostaining in cancer cells for SPARC 




Figure 3.4 Immunoreactivity of proteins expressed by CAF/ECM in baseline 
tumor with matched adjacent normal tissue (a, c, e, g and i) CAF/ECM proteins 
expression in adjacent normal tissue. (b, d, f, h and j) CAF/ECM proteins expression 
in matched baseline tumor. Magnification ×100. 
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3.3.1.3 Prognostic Values of CAF/ECM Proteins in the Primary Cohort 
3.3.1.3.1 Association between High Baseline CAF/ECM Proteins 
Expression with Poor Survival  
High baseline THBS1 (Figure 3.5b) and SPARC (Figure 3.5h) were 
significantly associated with poorer OS, and high baseline SPARC was an 
independent prognostic marker in multivariate analysis for OS (HRadjusted 3.78, 
95% CI 1.03-13.92, p=0.045), adjusted for age, tumor grade, metastasis, tumor 
size, pathological lymph node involvement, ER, PR and Her2 status. Other 
individual baseline CAF/ECM proteins were not associated with either PFS or 
OS.  
Strikingly, high baseline combined score for CAF/ECM proteins was 
significantly associated with both shorter PFS (mean PFS 33.9 [95% CI 23.6-
44.2] vs 52.3 [95% CI 41.4-63.2] months for high vs low CAF/ECM 
combined score, p=0.041, Figure 3.5k) and OS (mean OS 45.6 [95% CI 36.4-
54.8] vs 70.2 [95% CI 60.0-79.5] months for high vs low CAF/ECM 
combined score, p=0.001, Figure 3.5i). In multivariate analysis, high baseline 
CAF/ECM combined score was an independent predictor for both poorer PFS 
(HRadjusted 2.22, 95% CI 1.06-4.64, p=0.034) and OS (HRadjusted 5.94, 95% 















Figure 3.5 Association between baseline CAF/ECM protein expression and 
progression-free and overall survival (a-b) THBS1; (c-d) TNC; (e-f) FN; (g-h) 
SPARC; (i-j) α-SMA; (k-i) combined baseline CAF/ECM score. 
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Table 3.6 Univariate and multivariate analysis of correlation between baseline proteins expression of CAF/ECM and progression-free and overall 
survival in the primary cohort 
 
Crude HR (95% CI) pc Adjusted HR pc Crude HR (95% CI) pc Adjusted HR pc 
THBS1
  Low 39 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
  High 27 1.45 (0.79-2.65) NS 0.95 (0.46-2.02) NS 2.27 (1.12-4.60) 0.023 2.06 (0.71-5.99) NS
  Unknownd 29 1.17(0.63-2.16) NS 1.12 (0.47-2.66) NS 1.50 (0.71-3.16) NS 2.92 (1.12-7.67) NS
TNC 
  Low 43 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
  High 36 1.47 (0.85-2.56) NS 1.12 (0.55-2.27) NS 1.72 (0.92-3.20) NS 1.38 (0.60-3.17) NS
  Unknownd 16 1.03 (0.60-2.14) NS 1.41 (0.52-3.85) NS 0.93 (0.37-2.34) NS 0.63 (0.18-2.21) NS
FN 
  Low 30 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) NS 1.00 (Ref.)
  High 50 0.99 (0.56-1.74) NS 1.10 (0.48-2.49) NS 1.02 (0.53-1.97) NS 1.87 (0.65-5.39) NS
  Unknownd 15 1.03 (0.48-2.20) NS 1.05 (0.35-3.20) NS 1.25 (0.53-2.99) NS 0.98 (0.25-3.81) NS
α-SMA
  Low 56 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) NS 1.00 (Ref.)
  High 15 1.49 (0.78-2.89) NS 0.67 (0.28-1.58) NS 1.83 (0.88-3.81) NS 2.17 (0.86-5.50) NS
  Unknownd 24 0.84 (0.45-1.59) NS 1.05 (0.48-2.27) NS 0.93 (0.45-1.94) NS 1.97 (0.80-4.83) NS
SPARC
  Low 18 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) NS 1.00 (Ref.)
  High 11 1.65 (0.66-4.12) NS 1.56 (0.55-4.43) NS 3.52 (1.20-10.33) 0.022 3.78 (1.03-13.92) 0.045
  Unknownd 66 1.13 (0.58-2.20) NS 1.05 (0.44-2.50) NS 1.75 (0.73-4.21) NS 1.22 (0.39-3.87) NS
Combined 
  Low 39 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
  High 39 1.79 (1.02-3.14) 0.044 2.22 (1.06-4.64) 0.034 3.17 (1.56-6.44) 0.001 5.94 (2.25-15.71) <0.001
CAF/ECM proteins N a 
PFS OS
a5 baseline core biopsies without tumor presence were excluded;  bAdjusted for age, tumor grade, metastasis, tumor size, 




3.3.1.3.2 Association between High Post-treatment CAF/ECM Proteins 
Expression with Poor Survival  
While high baseline α-SMA expression only showed a trend in association 
with shorter survival (Figure 3.5i-j), high α-SMA in post-treatment specimens 
following 1 cycle of chemotherapy was associated with both shorter PFS 
(mean PFS 29.0 [95% CI 14.3-43.7] vs 52.4 [95% CI 42.9-63.0] months for 
high vs low α-SMA, p=0.033, Figure 3.6i) and OS (mean OS 43.0 [95% CI 
27.2-58.7] vs 67.5 [95% CI 52.9-75.8] months for high vs low α-SMA, 
p=0.012, Figure 3.6j). Expression of other CAF/ECM proteins at cycle 1 was 








Figure 3.6 Association between CAF/ECM protein expression at cycle 1 and 
progression-free and overall survival (a-b) THBS1; (c-d) TNC; (e-f) FN; (g-h) 




Similarly,  high α-SMA in post-treatment specimens following 2 cycles of 
chemotherapy remained significantly associated with both shorter PFS (mean 
PFS 13.7 [95% CI 8.10-19.2] vs 51.2 [95% CI 40.6-61.8] months for high vs 
low α-SMA, p<0.001, Figure 3.7i) and OS (mean OS 25.6.0 [95% CI 15.4-
35.9] vs 69.5 [95% CI 61.4-77.6] months for high vs low α-SMA, p<0.001, 
Figure 3.7j). High expression of TNC at cycle 2 was also associated with short 
OS (p=0.047; Figure 3.7d). Expression of the other CAF/ECM proteins at 







Figure 3.7 Association between CAF/ECM protein expression at cycle 2 and 
progression-free and overall survival  (a-b) THBS1; (c-d) TNC; (e-f) FN; (g-h) 




3.3.1.4 Increased Expression of CAF/ECM Proteins Following 
Chemotherapy in the Primary Cohort 
Concordant with previous findings (88), baseline expression in TNC and FN 
showed mild positive association (Spearman correlation=0.324, p=0.005). No 
further associations were found between the expression of the 5 CAF/ECM 
proteins both at baseline and after treatment. Figure 3.8 showed the expression 
alterations of THBS1 (n=66), TNC (n=79), FN (n=80), α-SMA (n=50) and 
SPARC (n=62) after the first and second cycle of chemotherapy. There was 
statistically significant up-regulation of THBS1 and TNC expression after 
both cycle 1 and cycle 2 chemotherapy compared with baseline (mean THBS1 
expression 1.27±0.92, 1.52±0.88, 1.50±0.85 for baseline, cycle 1 and cycle 2, 
p=0.008 for cycle 1 vs baseline, p=0.019 for cycle 2 vs baseline; mean TNC 
expression 2.32±0.71, 2.63±0.57, 2.54±0.72 for baseline, cycle 1 and cycle 2, 
p=0.001 for cycle 1 vs baseline, p=0.037 for cycle 2 vs baseline). FN 
expression increased significantly after 1 cycle of chemotherapy (mean 
expression 1.88±0.79 vs 2.19±0.76 for baseline vs cycle 1, p=0.041). Similarly, 
trends of increasing IHC expression were observed in post-treatment 
specimens for α-SMA and SPARC, although the difference did not reach 
statistical significance. Taken together, chemotherapy was observed to 
significantly increase CAF/ECM proteins expression (THBS1, TNC and FN) 
and in particular, induce persistent increased expression of THBS1 and TNC 
compared with FN, suggesting that THBS1 and TNC may play more 





Figure 3.8 Increase in CAF/ECM protein expression following neoadjuvant 
chemotherapy in the primary cohort Mean expression of THBS1, TNC, FN, 
SPARC and α-SMA at baseline, after cycle 1 and after cycle 2 chemotherapy. * 




3.3.1.5 Chemotherapy-induced CAF/ECM Proteins Expression Changes 
in relation to Estrogen Receptor Status in the Primary Cohort  
At baseline, there was no significant difference in the expression levels of all 5 
CAF/ECM proteins analyzed between ER negative and positive tumors (Table 
3.7). 
Table 3.7 Relation between baseline proteins expression by CAF/ECM and 
tumor ER status 
However, significant increase in the expression of THBS1 and TNC was 
observed after the first and second chemotherapy cycle in ER positive tumors 
(mean THBS1 1.00±0.82, 1.60±0.97, 1.53±0.88 for baseline, cycle 1 and cycle 
2, change 60.00% and 53.13% from baseline, p=0.001 and p=0.012; mean 
TNC 2.19±0.74, 2.62±0.56, 2.63±0.60 for baseline, cycle 1 and cycle 2, 
change 19.42% and 19.29% from baseline, p=0.006 and p=0.021 for cycle 1 or 
cycle 2 vs baseline respectively, Table 3.8 and Figure 3.9). In contrast, no 
significant changes were seen in THBS1 and TNC expression for ER negative 
tumors. No significant differences in chemotherapy-induced expression 




ER  status 
   
THBS1 
Negative 21 1.38±0.97 0.155 
Positive 36 1.00±0.83  
TNC 
Negative 31 2.52±0.68 0.065 
Positive 36 2.19±0.75 
 
FN 
Negative 29 1.86±0.79 0.772 
Positive 37 1.81±0.81   
SPARC 
Negative 21 1.05±0.86 0.491 
Positive 24 1.21±0.83 
 
α-SMA 
Negative 27 35.74±33.50 0.520 
Positive 27 30.04±27.56   
a: Mann-Whitney U test  
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changes were observed for FN, SPARC or α-SMA between ER positive and 
negative tumors. 
Table 3.8 Association between changes of CAF/ECM protein expression 
following chemotherapy and tumor ER status in the primary cohort 
 
Figure 3.9 Comparison of changes in THBS1 and TNC expression after cycle 1 
and 2 chemotherapy relative to baseline in ER positive and negative subgroups 
in the primary cohort * p<0.05, ** p<0.01 
  BL C1 C2 P
a
 (C1 




vs  BL)   Mean ±SD 
ER positive subgroup (n=37) 
THBS1 1.00±0.82 1.60±0.97 1.53±0.88 0.001 0.012 
TNC 2.19±0.74 2.62±0.56 2.62±0.60 0.006 0.021 
FN 1.81±0.81 2.11±0.80 2.23±0.92 0.279 0.061 
SPARC  1.21±0.83 1.25±1.00 1.38±0.98 0.979 0.182 
α-SMA 31.9±26.8 34.17±32.69 31.91±26.82 0.574 0.172 
ER negative subgroup (n=31) 
THBS1 1.38±0.97 1.52±0.81 1.42±0.81 0.248 0.623 
TNC 2.51±0.68 2.74±0.68 2.54±0.78 0.145 0.855 
FN 1.86±0.789 2.01±0.74 2.00±0.80 0.31 0.571 
SPARC  1.05±0.86 1.55±0.95 1.49±0.94 0.119 0.21 
α-SMA 35.7±33.5 42.39±28.52 47.7±29.0 0.735 0.649 
a
Wilcoxon Signed Ranks Test; ER: estrogen receptor; BL: baseline; C1: cycle 1; 
C2: cycle 2 
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3.3.1.6 Chemotherapy-induced CAF/ECM Proteins Expression Changes 
in relation to Tumor Human Epidermal Growth Receptor 2 
Status in the Primary Cohort 
At baseline, there was no significant difference in the expression levels of all 5 
CAF/ECM proteins analyzed between Her2 negative and positive tumors 
(Table 3.9).  
Table 3.9 Relation between baseline proteins expression by CAF/ECM and 
tumor Her2 status 
Interestingly, significant increase in the expression of THBS1 and TNC was 
observed after the first or second chemotherapy cycle in Her2 negative tumors 
(mean THBS1 1.14±0.85, 1.45±0.93, 1.41±0.91 for baseline, cycle 1 and cycle 
2, change 27.19% and 23.68% from baseline, p=0.021 and p=0.019; mean 
TNC 2.25±0.74, 2.60±0.58, 2.54±0.78 for baseline, cycle 1 and cycle 2, 
change 15.56% and 12.89% from baseline, p=0.010 and p=0.051 for cycle 1 or 
cycle 2 vs baseline respectively, Table 3.10). In contrast, no significant 
changes were seen in THBS1 and TNC expression for Her2 positive tumors. 
No significant differences in chemotherapy-induced expression changes were 





   
THBS1 
Negative 44 1.14±0.85 0.207 
Positive 16 1.50±1.01  
TNC 
Negative 51 2.25±0.74 0.132 
Positive 20 2.55±0.61  
FN 
Negative 53 1.85±0.79 0.232 
Positive 19 2.11±0.81   
SPARC 
Negative 38 1.18±0.90 0.792 
Positive 13 1.08±0.76  
α-SMA 
Negative 44 35.57±31.64 0.948 
Positive 17 36.53±31.64   
a: Mann-Whitney U test  
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observed for FN, SPARC or α-SMA between Her2 positive and negative 
tumors. 
Table 3.10 Changes of CAF/ECM protein expression following chemotherapy 
and their association with tumor Her2 status 
3.3.1.7 Increased Expression of CAF/ECM Proteins with Chemotherapy 
in Intrinsically Resistant Tumors in the Primary Cohort 
Baseline expression of all 5 CAF/ECM proteins was not significantly different 
between intrinsically sensitive (IS) and intrinsically resistant (IR) tumors 
(Table 3.11). After 1 cycle of chemotherapy, there were also no significant 
chemotherapy-induced changes from baseline for the expression of all 5 
CAF/ECM proteins between IS and IR tumors (Figure 3.10a). However, 
following two cycles of chemotherapy, increased expression of both THBS1 
and TNC was observed in IR tumors (mean THBS1 1.30±0.75 vs 1.62±0.82, 
change 24.62%, p=0.007; mean TNC 2.31±0.63 vs 2.65±0.61, change 14.72%, 
p=0.017; Figure 3.10b). In contrast, no significant up-regulation in THBS1 







BL)   Mean±SD 
Her2 positive subgroup (n=20) 
THBS1 1.50±1.01 1.59±0.80 1.67±0.59 0.238 0.623 
TNC 2.19±0.74 2.70±0.57 2.73±0.59 0.102 0.739 
FN 2.11±0.81 2.30±0.80 2.11±0.83 0.051 0.862 
SPARC  1.07±0.76 1.29±0.83 1.31±0.87 0.16 0.655 
α-SMA 36.53±31.64 45.50±30.86 43.15±32.59 0.498 0.75 
Her2 negative subgroup (n=51) 
THBS1 1.14±0.85 1.45±0.93 1.41±0.91 0.021 0.019 
TNC 2.25±0.744 2.60±0.58 2.54±0.78 0.010 0.051 
FN 1.85±0.79 2.15±0.74 2.16±0.87 0.301 0.081 
SPARC  1.18±0.90 1.38±1.08 1.31±1.00 0.937 0.353 
α-SMA 32.50±28.63 42.39±28.52 31.73±24.41 0.58 0.627 
a
Wilcoxon Signed Ranks Test; BL: baseline; C1: cycle 1; C2: cycle 2 
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and TNC was seen in patients with IS tumors (mean THBS1 1.25±1.05 vs 
1.39±0.87, p=0.432; mean TNC 2.32±0.77 vs 2.46±0.79, p=0.385). No 
significant differences in chemotherapy-induced expression changes in FN, 
SPARC or α-SMA were observed between IS and IR tumors following 2 
cycles of chemotherapy. 
Table 3.11 Relation between baseline proteins expression by CAF/ECM and 








Resistant 30 1.30±0.75 0.730 
Sensitive 36 1.25±1.05 
 
TNC 
Resistant 35 2.31±0.63  0.779 
Sensitive 44 2.32±0.77 
 
FN 
Resistant 38 1.76±0.79 0.218 
Sensitive 42 1.98±0.78 
 
SPARC 
Resistant 26 1.04±0.96 0.454 
Sensitive 35 1.17±0.78 
 
α-SMA 
Resistant 31 29.68±27.96 0.454 
Sensitive 39 34.00±31.16    







Figure 3.10  Comparison of changes in CAF/ECM proteins after cycle 1 and 
cycle 2 chemotherapy relative to baseline in intrinsically sensitive (IS) and 
resistant (IR) tumors in the primary cohort   (a) post-cycle-1; (b) post-cycle-2; * 




3.3.1.8 Up-regulation of CAF/ECM Proteins following 1 and 2 Cycles of 
Neoadjuvant Chemotherapy Correlated with Subsequent 
Pathological Lymph Node Involvement in the Primary Cohort 
Baseline expression of CAF/ECM proteins did not differ significantly between 
patients with or without PLN involvement at surgery, except for FN, whose 
basal expression was higher in patients without PLN involvement (p=0.036; 
Table 3.12). However, after 1-2 cycles of chemotherapy, patients who had 
PLN involvement at surgery showed significant up-regulation of tumor 
THBS1, TNC, FN, SPARC and α-SMA expression (Figure 3.11). After one 
cycle of chemotherapy, there was significant THBS1 and TNC up-regulation 
in relation to baseline (mean THBS1 1.25±0.93 vs 1.63±0.88, change 30.40%, 
p=0.003; mean TNC 2.18±0.79 vs 2.55±0.55, change 16.97%, p=0.015) 
compared to patients without PLN involvement (mean THBS1 1.25±1.00 vs 
1.33±0.86, change 6.40%, p=0.166; mean TNC expression 2.30±0.57 vs 
2.65±0.57, change 15.22%, p=0.083). Similarly, compared to baseline, up-
regulation of FN, SPARC and α-SMA following 2 cycles of chemotherapy 
was observed in tumors from patients with PLN involvement (mean FN 
1.66±0.80 vs 2.45±0.77, change 47.59%, p=0.005; mean SPARC 0.94 ±0.77 
vs 1.40±1.10, change 49.33%, p=0.046; mean α-SMA 25.8±27.4 vs 36.8±29.7, 
change 42.64%, p=0.021). In contrast, there were no significant 
chemotherapy-induced tumor expression changes in FN, SPARC and α-SMA 
in patients without PLN involvement (mean FN 2.10 ±0.72 vs 2.55±0.76, 
change 20.85%, p=0.284; mean SPARC 1.23±0.86 vs 1.39±0.98, change 
12.70%; mean α-SMA 36.90±31.80 vs 30.30±25.20, change -17.89%, 
p=0.205). These results suggest that increase in expression of THBS1, TNC, 
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FN, SPARC and α-SMA early in the course of neoadjuvant chemotherapy 
may be predictive of PLN metastasis and hence poorer clinical outcomes; both 
THBS1 and TNC may be better predictors than FN, SPARC and α-SMA as 
changes occurred earlier.  
Table 3.12 Relation between baseline proteins expression by CAF/ECM and 









Negative 16 1.25±1.00  0.98 
Positive 28 1.25±0.93 
 
TNC 
Negative 20 2.30±0.57  0.683 
Positive 34 2.18±0.80 
 
FN 
Negative 20 2.10±0.72 0.036 
Positive 35 1.66±0.80 
 
SPARC 
Negative 16 1.23±0.86 0.278 
Positive 26 0.94±0.77 
 
α-SMA 
Negative 18 36.04±31.77  0.277 
Positive 32 25.78±27.42   






Figure 3.11 Comparison of changes in CAF/ECM proteins expression after 
chemotherapy relative to baseline in pathological lymph node positive and 
negative tumors in the primary cohort (a) post-cylce-1; (b) post-cycle-2; * p<0.05, 




3.3.1.9 Clinicopathological Characteristics of the Validation Cohort 
The median age of this cohort was 50 years (range 31-63, Table 3.13). The 
median follow-up time was 54.8 months (range 3.0-67.0). Mean PFS and OS 
were 48.0 [95% CI 38.7-57.3] and 52.8 [95% CI 44.7-60.8] months, 
respectively.  In the primary cohort, we have shown, among 5 CAF/ECM 
proteins, that both THBS1 and TNC were more related with chemotherapy 
resistance, including intrinsic resistance and lymph node involvement at 
surgery. Therefore, we further validated the prognostic and predictive values 
of THBS1 and TNC in this independent cohort.  
Table 3.13 Clinicopathological characteristics of the validation cohort  
   (n, %) 
Age   
<50 15 (48) 
>=50 16 (52) 
Ethnicity 
 Chinese 14 (45) 
Malay & others 17 (55) 
Tumour grade 
 1 2 (7)  
2 10 (32)  
3 19 (61)  
T4 stage 
 No 19 (61) 
Yes 12 (39) 
Metastasis 
 No 22 (71) 
Yes 9 (29) 
25% tumour reduction at cycle 1 
 <25% 15 (48) 
≥25% 16 (52) 
Pathological lymph node involvement 
a
  
 No  7 (24) 
Yes 22 (76) 
a:29 patients underwent surgery 
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3.3.1.10 Validation of Chemotherapy-Induced Expression Changes in 
THBS1 and TNC in an Independent Cohort  
Consistently, both THBS1 and TNC expression showed progressively 
increasing trends from baseline, cycle 1 to cycle 4 (mean THBS1 1.05±0.94, 
1.30±0.89, 1.70±0.66, p=0.020; mean TNC 2.11±0.81, 2.21±0.63, 2.42±0.77, 
p=0.232). Patients with IR tumors had significant increase in TNC expression 
in post-cycle-4 tumor specimens compared to baseline (mean 2.14±0.66, 
2.33±0.62, 2.50±0.80 for baseline, cycle 1 and cycle 4, change 8.89% and 
p=0.102 for cycle 1 vs baseline; change 16.67% and p=0.034 for cycle 4 vs 
baseline; Figure 3.12a). As in the primary cohort, patients with PLN had 
significant increase in THBS1 expression in both the post-cycle-1 and post-
cycle-4 tumor specimens compared to baseline (mean THBS1 0.72±0.83, 
1.06±0.80, 1.41±0.62 for baseline, cycle 1 and cycle 4, change 46.16% and 
p=0.034 for cycle 1 vs baseline; change 95.49% and p=0.032 for cycle 4 vs 
baseline; Figure 3.12b). An increasing trend was observed in TNC expression 
in patients with pathologically involved lymph nodes (change 8.33% for cycle 
1 vs baseline; change 25% for cycle 4 vs baseline) although the difference was 
not statistically significant (Figure 3.12b). Taken together, both THBS1 and 
TNC expression changes in relation to chemotherapy and treatment response 
in this independent dataset were consistent with our findings in the primary 





Figure 3.12 Association between increased THBS1 and TNC expression and 
chemoresistance following neoadjuvant chemotherapy in the validation cohort  
Changes in THBS1 and TNC expression after cycle 1 and cycle 4 chemotherapy 
relative to baseline (a) in patients with intrinsically sensitive (IS) and resistant (IR) 




We did not find significant association between these two ECM proteins with 
either PFS or OS, at both baseline and post-treatment levels, in the validation 
cohort. This may be due to the relatively small sample size of the validation 
cohort: n=19 or 6 for low or high THBS1 expression subgroups; n=16 or 11 
for low or high TNC expression subgroups respectively. 
In summary, we studied the prognostic roles of CAF/ECM in breast cancer 
development and their predictive values for chemotherapy response. In the 
primary cohort, we found that high baseline SPARC as well as high post-
treatment TNC and α-SMA were associated with poor survival of breast 
cancer patients, respectively; high expression of combined baseline CAF/ECM 
protein predicted independently for both poor progression-free and overall 
survival. After chemotherapy, increased expression of THBS1 and TNC 
compared to baseline was seen in ER+ tumors and intrinsically resistant 
tumors, respectively; increased expression in THBS1, TNC, FN, SPARC and 
α-SMA relative to baseline was seen in patients with pathological lymph node 
involvement, with changes occurring earlier for THBS1 and TNC. In the 
validation cohort, following chemotherapy, patients with intrinsically resistant 
tumors had significant increase in TNC expression; patients with pathological 
lymph node involvement had significant increase in THBS1 expression. Both 
THBS1 and TNC expression changes in relation to treatment response in the 
validation cohort were consistent with our findings in the primary cohort and 
confirmed their association with chemoresistance. The clinical findings for 




Figure 3.13 Schema of clinical findings for CAF/ECM proteins in breast cancer 




3.3.2 Prognostic and Predictive Values of Integrin Proteins in Breast 
Cancer  
In the previous Section, the prognostic roles and predictive values of 5 
CAF/ECM proteins (THBS1, TNC, FN, SPARC and α-SMA) for 
chemotherapy resistance were studied. THBS1, TNC, FN, and SPARC are 
also known as ECM proteins, whose binding to integrins on tumor cell surface 
can activate intracellular signaling to promote tumor cell growth and motility. 
Breast cancer cells exhibit increased expression of certain integrins, including 
integrin subunit α6 (74, 75), α9 (76) and β1(74, 76). In particular, significant 
up-regulation of these 3 subunits of integrins were found in tumors with high 
ECM content, revealed by previous gene expression studies on breast cancer 
specimens (89). Increased expression of integrins has been long proposed to 
be associated with metastatic capability of breast cancer, poor survival and 
high risk of recurrence (89). In addition, both subunits α6 and α9 are partners 
of β1 subunit in breast cancer (76). Importantly, these 3 integrin subunits are 
key components of the integrin receptors for ECM proteins THBS1 (α6 and 
β1), TNC (α9 and β1), FN (β1) and SPARC (α9 and β1), respectively (77, 90). 
Therefore, we proposed that interaction between ECM proteins THBS1, TNC, 
FN and SPARC and integrin subunits α6, α9 and β1 on the surface of breast 
cancer cells play an important role in regulating breast cancer progression and 
chemotherapy response. Current understanding of the primary changes of 
integrin subunits α6, α9 and β1 in neoadjuvant chemotherapy is limited. Thus, 
we further studied the alterations of integrin α6, α9 and β1 expression in 




3.3.2.1 Association between High Baseline Tumor Integrin β1 
Expression and ER and Her2 Status in the Primary Cohort 
At baseline, significantly higher expression of integrin β1 was observed in ER 
negative and Her2 positive tumors respectively (mean expression 83.06±75.36 
vs 167.20±99.98, p=0.001 for ER positive and negative tumors; 180.56±83.13 
vs 94.44±88.59, p=0.001 for Her2 positive and negative tumors). There was 
no significant difference in the levels of integrin α6 and α9 proteins either 
between ER positive and ER negative tumors or between Her2 positive and 
Her2 negative tumors. No correlations were observed between baseline 
expression of these integrin proteins and intrinsic tumor response (Table 3.14). 
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Table 3.14 Relation between baseline expression of integrin proteins and ER 
status, Her2 status and intrinsic response in the primary cohort 
Integrin proteins N Mean±SD P
a
  
  ER status       
α6 Negative 24 148.33±54.27 0.794 
Positive 37 153.51±72.77  
α9 Negative 20 76.25±80.38 0.650 
Positive 29 62.07±62.30 
 β1 Negative 25 167.20±99.98 0.001 




   α6 Negative 48 137.92±67.12 0.481 
Positive 18 151.11±72.26  
α9 Negative 40 61.38±69.29 0.861 
Positive 15 65.00±63.89 
 β1 Negative 45 94.44±88.59 0.001 
Positive 18 180.56±83.13 
 
 
Intrinsic response  
  α6 Resistant 31 151.29±74.80 0.421 
Sensitive 40 137.75±65.81  
α9 Resistant 28 75.54±76.83 0.119 
Sensitive 37 49.05±58.43 
 β1 Resistant 30 112.33±80.72 0.386 
Sensitive 39 132.56±105.22 
 




3.3.2.2 Association between Tumor Expression of Integrin Proteins and 
Breast Cancer Survival in the Primary Cohort 
Patients were classified into 2 subgroups for each integrin protein: low and 
high integrin expression subgroups, using the cut-off score for each integrin 
subunit. The representative IHC pictures and sample size for subgroups of 
each individual protein were showed in Figure 3.14.  
 
Figure 3.14 Representative pictures for low and high expression of each 
individual integrin subunit protein (a-b) Integrin α6; (c-d) Integrin α9; (e-f) 




3.3.2.2.1 Association between Baseline Tumor Expression of Integrin 
Proteins and Breast Cancer Survival in the Primary Cohort 
High baseline integrin α6 (Figure 3.15a-b) and integrin β1 (Figure 3.15e-f) 
were associated with poorer PFS (mean PFS 37.6 [95% CI 28.0-47.1] vs 55.2 
[95% CI 41.0-69.3] months for high vs low baseline α6, p=0.034; mean PFS 
34.7 [95% CI 23.8-45.6] vs 51.1 [95% CI 38.8-63.5] months for high vs low 
baseline integrin β1, p=0.072) and OS (mean OS 53.7 [95% CI 44.5-63.0] vs 
68.1 [95% CI 55.9-80.4] months for high vs low baseline integrin α6, p=0.036; 
mean OS 48.6 [95% CI 37.0-60.1] vs 67.9 [95% CI 58.7-77.0] months for 
high vs low baseline integrin β1, p=0.042). Baseline expression of integrin α9 
was not associated with either PFS or OS. 
In multivariate analysis, both high baseline integrin α6 and integrin β1 were 
independent prognostic markers for PFS but not for OS, after adjustment for 
other conventional prognostic markers including age, tumor grade, tumor size, 
ER, PR and Her2 status, pathological lymph node involvement and metastasis 
(HRadjusted 4.34, 95% CI 1.05-17.90, p=0.042 for integrin α6; HRadjusted 4.71, 




Figure 3.15 Association between baseline tumor expression of integrin proteins 
and progression-free and overall survival (a-b) integrin α6; (c-d) integrin α9; (e-f) 




Table 3.15 Univariate and multivariate analysis of baseline integrin proteins for progression-free and overall survival in the primary 
cohort 
Integrin  N 
PFS   OS 






















α6                     








  High 47 2.06 (1.04-4.09) 0.038 4.34 (1.05-17.90) 0.042 
 
2.40 (1.03-5.56) 0.042 1.74 (0.45-6.78) NS 
α9 








  High 45 1.13(0.58-2.22) NS 0.56 (0.18-1.68) NS 
 
1.77 (0.76-4.12) NS 0.68 (0.20-2.36) NS 
β1 








  High 39 1.73 (0.96-3.18) NS 4.71 (1.05-21.15) 0.043   2.04 (1.01-4.12) 0.046 2.35 (0.45-12.41) NS 
a 
adjusted for age, tumor grade, tumor size, ER status, PR status and Her2 status, lymph node involvement, metastasis; 
b
 Cox regression models analysis; 




3.3.2.2.2 Association between Post-treatment Tumor Expression of 
Integrin Proteins and Breast Cancer Survival in the Primary 
Cohort 
In post-treatment specimens at cycle 1, high integrin α6 (Figure 3.16a-b) was 
significantly associated with shorter PFS (mean PFS 40.7 [95% CI 31.8-49.5] 
vs 70.9 [95% CI 53.0-88.7] months for high vs low expression, p=0.008) and 
with marginally shorter OS (mean OS 57.2 [95% CI 48.4-66.0] vs 77.3 [95% 
CI 65.7-88.8] months for high vs low expression, p=0.056). However, neither 
integrin α9 nor β1 expression in post-treatment tumors at cycle 1 was 




Figure 3.16 Association between integrin proteins expression after 1 cycle of 
chemotherapy and progression-free and overall survival  (a-b) integrin α6; (c-d) 




Furthermore, high integrin α6 expression in post-treatment specimens after 2 
cycles of chemotherapy was significantly associated with shorter OS (p=0.021, 
Figure 3.17b). Similarly, high integrin α9 in post-treatment specimens after 2 
cycles of chemotherapy was marginally associated with shorter OS (p=0.051, 
Figure 3.17d), whereas integrin β1 expression at cycle 2 was not associated 





Figure 3.17 Association between integrin proteins expression at cycle 2 and 





In summary, baseline expression levels of integrin β1 and pre- and post-
chemotherapy expression levels of integrin α6 were associated with poor 
survival of breast cancer patients. Integrin α6 appears to be a more important 
integrin protein in regulating breast cancer progression as it was related to 
worse survival at all timepoints of treatment: baseline, post-cycle 1 and post-
cycle 2.   
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3.3.2.3 Changes in Integrin Proteins Expression Following 
Chemotherapy in the Primary Cohort  
To determine the changes in integrin protein expression upon exposure to 
chemotherapy, semi-quantitative IHC scores from post-treatment tumors were 
compared with those from matched pre-treatment tumors. Figure 3.18 showed 
the mean expression of integrin α6 (n=71), integrin α9 (n=79) and integrin β1 
(n=69) after the first and second cycle of chemotherapy. There was 
statistically significant up-regulation of integrin α6 expression after both cycle 
1 and cycle 2 chemotherapy compared with baseline (mean integrin α6 
expression 140.6±68.0, 167.6±55.0, 184.7±74.1 for baseline, cycle 1 and cycle 
2, p=0.007 for cycle 1 vs baseline, p=0.010 for cycle 2 vs baseline). Integrin 
β1 expression increased significantly after 2 cycle of chemotherapy (mean 
integrin β1 expression 114.2±95.2 vs 145.7±91.0 for baseline vs cycle 2, 
p=0.024). Similarly, increasing trends in integrin α9 was observed in post-
treatment specimens, although the difference did not reach statistical 
significance. Taken together, following chemotherapy, significant increase in 
both integrin α6 and integrin β1 proteins expression was obvious, suggesting 
that integrin α6 and integrin β1 may play more important roles in regulating 
response to doxorubicin- and docetexal-based chemotherapy. Integrin α6 and 
integrin β1 form the heterodimeric receptor for THBS1, which has been 
shown to be associated with chemotherapy resistance in the previous Section. 
These data suggest that THBS1/integrin β1/integrin α6 signaling may play a 
role in regulating chemotherapy resistance, which warrants further 




Figure 3.18 Increased expression of integrin proteins following neoadjuvant 
chemotherapy in the primary cohort Mean expression in integrin α6, α9 and β1 at 





3.3.2.4 Increased Integrin α6 Correlated with Subsequent Pathological 
Lymph Node Involvement in the Primary Cohort 
Baseline levels of integrin α6, α9 and β1 did not differ significantly between 
patients with or without pathological lymph node involvement at surgery 
(Table 3.16). However, after 1 and 2 cycles of chemotherapy, patients who 
had pathological lymph node involvement at surgery showed significant up-
regulation in integrin α6 expression (mean integrin α6 136.0±76.2, 180.6±58.5 
and 188.9±59.1 for baseline, cycle 1 and cycle 2, change 32.8% and 38.9% 
from baseline, p=0.025 for cycle 1 vs baseline, p=0.030 for cycle 2 vs baseline, 
n=27) compared to those without pathological lymph node involvement at 
surgery (mean integrin α6 135.0±70.1, 148.3±43.8 and 158.1±77.0 for 
baseline, cycle 1 and cycle 2, change 9.0% and 17.1% from baseline, p=0.146 
for cycle 1 vs baseline, p=0.694 for cycle 2 vs baseline, n=16). In contrast, 
there were no significant differences in chemotherapy-induced expression 
changes in integrin α9 and integrin β1 between patients with or without 
pathological lymph node involvement (Figure 3.19). These results suggest that 
increase in integrin α6 in response to neoadjuvant chemotherapy may be a 




Table 3.16 Relation between baseline integrin proteins and pathological lymph 
node involvement at surgery in the primary cohort 
 
Figure 3.19 Association between integrin proteins and pathological lymph node 
involvement in the primary cohort Changes in mean expression from baseline 
following 1 and 2 cycles of chemotherapy in pathological lymph node (LN) positive 










Negative 18 135.00±70.06 0.964 
Positive 30 136.00±76.23  
α9 
Negative 21 50.95±63.95 0.522 
Positive 26 63.65±69.45  
β1 
Negative 16 149.38±101.55 0.087 
Positive 28 100.00±82.87   
a: Mann-Whitney U test  
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3.3.2.5 Validation of Prognostic and Predictive Values of Integrin α6 in 
an Independent Cohort 
In the primary cohort, among 3 integrin proteins tested, only integrin α6 
showed both prognostic and predictive values, suggesting that it may be a 
more important integrin protein than integrin α9 and β1 in regulating breast 
cancer progression and chemotherapy response. As such, we further validated 
the prognostic and predictive significance of integrin α6 in an independent 
cohort of 31 breast cancer patients who received 4 cycles of preoperative 
docetaxel.  
Concordant with what was observed in the primary cohort, integrin α6 
expression increased in post-treatment tumors compared with baseline (mean 
integrin α6 expression 158.2±74.8, 214.1±66.2, 226.8±63.7 for baseline, cycle 
1 and cycle 4, p=0.012 for cycle 1 vs baseline, p=0.001 for cycle 4 vs baseline, 
Figure 3.20a). As in the primary cohort, patients with pathologically involved 
axillary lymph nodes had significantly increasing levels of integrin α6 with 
chemotherapy (mean integrin α6 expression 164.7±77.2, 216.8±57.9, 
223.5±75.5 for baseline, cycle 1 and cycle 4, change 31.7% and 35.7% from 
baseline, p=0.017 for cycle 1 vs baseline, p=0.001 for cycle 4 vs baseline, 
n=17) compared with patients without lymph node involvement (mean 
integrin α6 expression 180.0±85.8, 222.5±80.2, 215.0±42.8 for baseline, cycle 
1 and cycle 4, change 23.6% and 19.4% from baseline, p=0.144 for cycle 1 vs 
baseline, p=0.273 for cycle 4 vs baseline, n=5, Figure 3.20b). Taken together, 
increase in integrin α6 in relation to chemotherapy and treatment response in 
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this independent dataset was consistent with our findings in the primary cohort 
and confirmed its association with chemoresistance. 
        
      
Figure 3.20 Association between integrin α6 and chemoresistance in the 
validation cohort (a) Mean expression in integrin α6 at baseline (BL), after cycle 1 
(C1) and cycle 4 (C4) chemotherapy; (b) Changes in mean expression of integrin α6 
from baseline after 1 and 4 cycles chemotherapy  in patients with or without 




In this validation cohort, survival data were only available for 25 patients 
(n=10 and n=15 for integrin α6 low and high expression subgroups, 
respectively). Probably due to the small sample size, the prognostic value of 
integrin α6 was not validated (Figure 3.21). 
 
Figure 3.21 Association between baseline integrin α6 expression and survival in 




In summary, we studied the prognostic roles of 3 integrin proteins (α6, α9 and 
β1) in breast cancer development and their predictive values for chemotherapy 
response. We found that pre- and post-chemotherapy levels of integrin protein 
α6 and pre-chemotherapy levels of integrins β1 were associated with poor 
survival of breast cancer patients. High baseline expression of integrin β1 was 
associated with both Her2 positivity and ER negativity. After chemotherapy, 
increased expression of integrin α6 compared to baseline was seen in patients 
with pathological lymph node involvement in the primary cohort, which was 
further confirmed in the validation cohort. The clinical findings for integrin 









3.3.3 THBS1 and TNC Protected MCF-7 Cells against Proliferation 
Inhibition Induced by Docetaxel through Activating Integrin 
β1/mTOR Pathway  
In two prospective clinical trials, we have shown that both THBS1 and TNC 
were associated with docetaxel treatment resistance, either administered 
sequentially with doxorubicin in the primary cohort, or as a single agent in the 
validation cohort. Docetaxel is an active chemotherapeutic agent that is 
commonly used in both early-stage and advanced breast cancer. Therefore, we 
went on to determine the underlying mechanisms by which THBS1 or TNC 
protects breast cancer cells from the cytotoxic effects of docetaxel. After 48 
hours treatment with recombinant THBS1 and TNC in the presence or absence 
of docetaxel respectively, the protective effects of THBS1 and TNC on MCF-
7 cells were measured by MTS assay and Western blot analysis. As shown in 
Figure 3.23, 5nM of docetaxel treatment caused around 30% arrest of cell 
growth, compared with vehicle controls. Exogenous THBS1 and TNC were 
able to rescue the growth of MCF-7 cells in a dose dependent manner 
(p=0.001 for THBS1, Figure 3.23a; p<0.001 for TNC, Figure 3.23b). At 
concentrations of 5l/ml, compared with docetaxel-treated groups, THBS1 
and TNC rescued MCF-7 cell growth by 50% and 40% respectively, which 
were close to the viability rate of individual vehicle control. Furthermore, 
immunoblotting analysis showed that docetaxel treatment led to cell cycle 
arrest by decreasing cyclin D1 and c-myc and by increasing tumor suppression 
gene p27. THBS1 treatment reversed docetaxel-induced cell cycle arrest by 
enhancing cyclin D1 and suppressing p27 expression (Figure 3.24a). In 
contrast, TNC blocked the inhibitory effects of docetaxel on cell cycle by 
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increasing c-myc expression (Figure 3.24b). Therefore, it appears that THBS1 
and TNC promote breast cancer cell proliferation through differential 
mechanisms. As for the involvement of integrin β1/mTOR, docetaxel 
treatment decreased the levels of integrin β1 and deactivated mTOR signaling 
by dephosphoylating both p70S6 at Thr389 and S6RP at Ser235/236. Both 
THBS1 and TNC restored integrin β1 expression and activated mTOR 
pathway by phosphorylating p70S6K and S6RP in a dose dependent manner 
(Figure 3.24a-b). Taken together, we confirmed that, in the presence of 
docetaxel, both THBS1 and TNC promoted MCF-7 cell proliferation through 






Figure 3.23 Exogenous THBS1 and TNC protected MCF-7 cells against growth 
inhibition induced by docetaxel MCF-7 cells grew in DMEM containing 5% CS-
FBS for 48 hours. Then recombinant protein THBS1(a) or TNC (b) at indicated 
concentration (0, 0.01, 0.1, 1 and 5μg/ml) was added into the media respectively and 
maintained for 48 hours, with the presence or absence of 5nM of docetaxel. MTS 
assay was performed. The protective effects of THBS1 or TNC were analyzed using 






Figure 3.24 THBS1 and TNC protected MCF-7 cells against proliferation 
inhibition by docetaxel through activating integrin β1/mTOR pathway and 
deregulating cell cycle proteins Western blots analysis were performed for 
biomarker of mTOR pathway and cell cycle. (a) THBS1; (b) TNC 
95 
 
In summary, functional studies showed that exogenous THBS1 protected 
MCF-7 cells against proliferation inhibition induced by docetaxel through 
deregulating cell cycle proteins cyclin D1 and p27 while TNC did so through 
increasing the expression of c-myc. Moreover, both THBS1 and TNC 
activated integrin β1/mTOR pathway by increasing integrin β1 expression and 
phosphorylating both p70S6k and S6RP. Therefore, THBS1 and TNC may be 
able to promote the growth of a subpopulation of breast cancer cells against 
the cytotoxic effects of chemotherapy drugs through activating integrin 
β1/mTOR pathway, which could explain our findings in clinical specimens 
that both THBS1 and TNC were associated with chemotherapy resistance. The 
findings for the functional studies are summarized in Figure 3.25. 
 
Figure 3.25 Schema of the mechanisms by which THBS1/TNC regulates 




Chemotherapy is a cornerstone treatment in patients with early and advanced 
breast cancer. However, primary and acquired resistance to chemotherapy 
exists. Recent findings have shown that ECM/integrin signaling could protect 
cancer cells from cytotoxic effects of chemotherapy (1, 53, 54). The pro-
survival function of CAF/ECM proteins and integrins in modulating 
proliferation and apoptosis of cancer cells has emerged as an intense area of 
research in order to understand their roles in mediating chemotherapy 
resistance.  
Unchallenged baseline tumor signatures reflect information on inherent tumor 
biology, including the degree of aggressiveness and intrinsic treatment 
sensitivity. However, treatment outcomes are determined by both the tumor’s 
intrinsic biology and its cellular response upon drug exposure. As we shown 
previously, compared to baseline signature, chemotherapy-induced tumor 
changes provide additional prognostic and predictive information in breast 
cancer patients (based on the primary cohort of patients in this thesis) (91). 
Therefore, both baseline and post-treatment tumors are valuable to 
prognosticate and predict chemotherapy sensitivity. Thus, in this thesis, we 
analyzed the prognostic values of CAF/ECM/integrin at both baseline and 
post-treatment levels. Moreover, obtaining a biopsy within 48 hour after 
chemotherapy could provide information on acute tumor responses (92, 93). In 
contrast, a later biopsy at 2-3 weeks offers information on subacute changes, 
which may be useful to predict outcomes with short-term treatment. Therefore, 
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differential treatment durations of chemotherapy are valuable to determine the 
optimal timing for the most informative post-treatment biopsy. In this thesis, 
we compared the changes of CAF/ECM/integrin biomarkers at post-treatment 
from baseline expression levels. This allows us to access more valuable 
information of chemotherapy resistance and further to provide insights into 
designing rational therapy to target biomarkers or signaling of 
chemoresistance; it also allows us to determine the optimal timing of post-
treatment biopsy for each individual biomarker with the maximum significant 
changes.  
In the first part of this thesis, we have shown the prognostic and predictive 
values of a panel of CAF/ECM proteins and integrins in the context of 
neoadjuvant chemotherapy and the underlying mechanism by which THBS1 
and TNC regulated chemotherapy resistance. In this Section, discussion will 
be presented according to the following sequence of 1) prognostic and 
predictive values of CAF/ECM proteins in breast cancer; 2) prognostic and 
predictive values of integrin proteins in breast cancer; 3) ECM/integrin 
signalling-protected cancer cell proliferation against chemotherapy through 
activating mTOR pathway. 
3.4.1 Prognostic and Predictive Values of CAF/ECM Proteins in Breast 
Cancer 
3.4.1.1 Prognostic Values of CAF/ECM Proteins in Breast Cancer 
Stromal fibroblasts are critical in promoting cell motility and thus promoting 
breast cancer progression (24, 94). TNC, α-SMA and SPARC, which represent 
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the abundance of cancer-associated fibroblasts, have been linked to shorter 
survival in breast cancer in respective studies based on their gene expression 
or protein expression levels, respectively(62, 67, 68, 95). In a prospective 
neoadjuvant clinical trial, we confirmed that high expression of baseline 
SPARC and post-treatment α-SMA and TNC was associated with shorter 
survival. Moreover, previous studies showed that cancer-associated stroma in 
invasive breast cancer independently predicted tumor recurrence, distant 
metastasis and subsequent poor clinical outcomes (58, 96) and stroma-derived 
26 genes could forecast disease outcome (58). Importantly, we showed that 
high expression of combined baseline stromal CAF/ECM proteins predicted 
for poor PFS and OS independently.  These results strongly suggest that these 
5 CAF/ECM proteins have a crucial role in prognosticating breast cancer and 
thus a combined CAF/ECM score model may be more useful to predict 
prognosis of breast cancer patients.  
3.4.1.2 Neoadjuvant Chemotherapy Increased CAF/ECM Protein 
Expression, particularly in ER Positive and Her2 Negative Breast 
Cancer respectively 
It was reported that up-regulation of stroma-related genes, encoding for 
fibroblast factors and CAF/ECM proteins, followed epirubicin- or taxane-
based neoadjuvant chemotherapy (92, 97), suggesting that stroma-related 
genes may play important roles in response or in mediating resistance to 
chemotherapy. In the context of doxorubicin- and docetaxel-based neoajuvant 
chemotherapy, we showed predominant up-regulation in THBS1, TNC and 
FN after 3 weeks of chemotherapy when compared with matched baseline 
specimens; the increase persisted after 6 weeks of chemotherapy for THBS1 
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and TNC, particularly in ER positive and Her2 negative tumors respectively. 
Several studies have suggested that stromal gene expression levels may be 
important clinical indicators of tumor response to either combined or single 
neoadjuvant chemotherapy in breast cancer. Farmer et al (59) showed that 
increased stromal gene expression in reactive stroma in breast cancer 
predicted resistance to preoperative chemotherapy with 5-fluorouracil, 
epirubicin and cyclophosphamide (FEC). SPARC is in the list of stromal gene 
signature identified by Farmer et al. Azim et al (98) further confirmed an 
association between high SPARC mRNA expression and low pathological 
complete response rate especially in the Her2 subtype following neoadjuvant 
anthracycline with or without taxanes (docetaxel or paclitaxel). Similarly, 
TNC protein expression was up-regulated in breast cancer patients with 
progressive disease treated with either anthracyclin- or taxane-based 
monotherapy (97). These suggest that CAF/ECM biomarkers could be used as 
predictive biomarkers for neoadjuvant chemotherapy resistance following 
common chemotherapy drugs currently administered in breast cancer patients. 
Therefore, the predictive value of CAF/ECM for chemotherapy resistance may 
be a general phenomenon in breast cancer. 
The high expression of CAF/ECM proteins in ER positive tumors may be 
associated with ER-stimulated differentiation of fibroblasts into 
myofibroblasts and formation of extracellular matrix (99, 100). Consistently, a 
previous study reported that THBS1 was directly stimulated by estrogens in 
ER positive breast cancer cells (101). However, data on the association 
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between high expression of THBS1 and TNC in Her2 negative breast cancer 
are very limited, and warrant further studies. Taken together, our results 
suggest that THBS1 and TNC may be the more important CAF/ECM proteins 
that respond to chemotherapy and thus may play crucial roles in regulating 
chemoresponse. 
3.4.1.3 Predictive Values of CAF/ECM Proteins in Breast Cancer 
An earlier result showed THBS1 promoted breast cancer to metastasize to 
lungs in the polyomavirus middle T antigen transgenic mouse, suggesting that 
THBS1 plays a role in mammary cancer cell migration (69). We found that 
tumors with pathological lymph node involvement at surgery following 
neoadjuvant chemotherapy had significant increase in THBS1 expression after 
one cycle of chemotherapy, which was independently confirmed in a second 
cohort. In concordance, increased expression of THBS1 following 
chemotherapy was also observed in intrinsically resistant tumors. Although the 
role of THBS1 in regulating tumor progression was controversial (102-104), 
in invasive cancer, THBS1 may function as an adhesive protein or a modulator 
of extracellular proteases to promote tumor invasion (69, 70).  
TNC on the other hand, plays a major role in promoting cell migration by 
remodeling cancer-associated stroma (105) and activating integrin pathway 
(106) and has thus been associated with local and distant recurrence (107). 
Breast cancer cell-derived TNC was essential in initiation and promotion of 
the outgrowth of pulmonary micrometastases (108), and high TNC expression 
was associated with treatment resistance to tamoxifen (62). In our study, 
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statistically significant up-regulation of TNC expression after 1-2 cycles of 
chemotherapy was observed in patients with intrinsically resistant tumors as 
well as those with pathological lymph node involvement at surgery. Enhanced 
regulation of cancer stem cell population may partially explain TNC-
associated resistance to conventional chemotherapy (108, 109). Furthermore, 
we found that increase in expression of FN, SPARC and α-SMA after two 
cycles of chemotherapy was associated with subsequent pathological lymph 
node involvement, and these ECM proteins may also promote metastasis 
through a stroma-remodeling manner. Collectively, increases in expression of 
CAF/ECM proteins a few weeks after chemotherapy were associated with 
treatment resistance and have the potential to serve as biomarkers to stratify 
breast cancer patients into distinct chemoresponse subgroups. 
In summary, we confirmed the prognostic and predictive roles of a panel of 
CAF/ECM proteins in the context of neoadjuvant chemotherapy in breast 
cancer. High baseline expression of combined CAF/ECM proteins was an 
independent predictor for poor progression-free and overall survival. Early up-
regulation in THBS1 and TNC after chemotherapy was more prominent in ER 
positive and Her2 negative tumors respectively, and was associated with 
intrinsic chemotherapy resistance and pathological lymph node involvement. 
Further assessments of these proteins may help establish the mechanisms that 
contribute to chemoresponse and uncover strategies to overcome resistance.  




The role of ECM-integrin interactions in cell migration and drug resistance 
has drawn attention in the last decade since it seems to be a general 
phenomenon that occurs in both solid and haematological malignancies. After 
assessing the prognostic and predictive roles of 4 ECM proteins in patients 
receiving neoadjuvant chemotherapy, we further determined the prognostic 
and predicative values of three integrin subunit proteins α6, α9 and β1, which 
form key components of the integrin receptors for ECM proteins THBS1 (α6 
and β1), TNC (α9 and β1), FN (β1), and SPARC (α9 and β1), in the same 
context of neoadjuvant chemotherapy from two prospective study cohorts by 
immunohistochemistry analysis.    
3.4.2.1 Association between Integrin β1 and ER Negative and Her2 
Positive Breast Cancer 
ER negative breast cancers are more aggressive and unresponsive to anti-
estrogen therapy. In this study, we have shown high baseline integrin β1 
expression in ER negative tumors. In addition, integrin signalling occurs in 
cooperation with growth factor signalling. For instance, integrins regulated the 
expression of Her2 and the subsequent phosphorylation of EGFR to promote 
the invasion of breast carcinoma cells (110). Consistent with a previous study 
showing up-regulation of integrin β1 in Her2 positive breast cancers in a 
retrospective study (111), we confirmed high expression of integrin β1 in Her2 
positive, treatment-naïve breast cancer. Integrin β1 has been reported to 
contribute to resistance to Her2-targeted therapy with lapatinib in breast 
cancer by mediating an alternative survival pathway (112). Therefore, 
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targeting integrin β1 may be a rational strategy to overcome Her2-targeted 
therapy resistance in Her2 positive breast cancers. 
3.4.2.2 Prognostic Values of Integrin Protein α6 and β1 in Breast Cancer 
Previous findings on retrospective studies have shown that high expression 
of integrin α6 was correlated with reduced survival of breast cancer (75, 113); 
increased integrin β1 was also predictive of shorter survival in breast cancer 
patients (86, 111, 114). In a prospective study, we confirmed that high 
baseline integrin α6 and β1 expression predicted poorer progression-free 
survival independent of conventional prognostic biomarkers, such as age, 
stage, lymph node involvement, ER, PR and Her2 status, in the primary study 
cohort. Strikingly, high expression of integrin α6 after 1 and 2 cycles of 
chemotherapy remained a powerful predictor for poorer survival. Therefore, 
integrin α6 at both baseline and post-treatment as well as integrin β1 at 
baseline could be used as biomarkers to stratify breast patients treated with 
chemotherapy into subgroups with favourable or unfavourable clinical 
outcomes.  
3.4.2.3 Chemotherapy Induced Increase in Integrin Proteins Expression 
A gene expression study has shown that chemotherapy induced changes of 
genes encoding various integrins in MCF-7 cell lines (115).  In particular, up-
regulation of integrin α6 was observed following chemotherapy in breast 
cancer cells (115, 116).  In clinical specimens, we showed significant up-
regulation of both integrin α6 and β1 following 1 and 2 cycles of docetaxel- 
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and doxorubicin-based chemotherapy, compared with their expression levels 
in matched baseline tumors respectively. Chemotherapy-induced increase in 
integrin α6 in relation to basal levels was reproducible in an independent 
dataset after 1 and 4 cycles of docetaxel. Our findings suggest that both 
integrin α6 and β1 are important integrins in response to chemotherapy drugs. 
Altered phenotypes in ECM-integrin signalling can affect the sensitivity of the 
tumor cells to cytotoxic drugs and subsequently facilitate the tumor to develop 
cell adhesion-mediated drug resistance. Therefore, integrin α6 and β1 may be 
potential indicators for chemotherapy response. 
3.4.2.4 Predictive Values of Integrin α6 to Chemotherapy in Breast 
Cancer 
Preclinical studies have shown the role of integrin α6 in chemotherapy 
resistance by its up-regulation in docetaxel or doxorubicin resistant breast 
cancer cells (115, 116). In clinical specimens, we found significant increase in 
integrin α6 relative to its expression levels in baseline tumors in patients with 
lymph node involvement at surgery following neoadjuvant chemotherapy, 
which was further confirmed in the validation cohort. Therefore, integrin α6 
appears to be an important indicator for prediction of chemotherapy resistance 
of breast cancer. The precise mechanism by which integrin α6 regulates 
chemotherapy resistance is still unclear, but may involve activation of PI3K 
and Src as well as increase in expression of pro-invasive and pro-metastatic 
genes in breast cancer cells (117).  
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In summary, we have shown the prognostic value of integrin protein α6 and β1 
for poor survival of breast cancer. Chemotherapy-induced increase in integrin 
α6 was associated with pathological lymph node involvement at surgery. 
Therefore, both integrin protein α6 and β1 could be used as prognostic 
biomarkers while integrin α6 may also be a potential biomarker to predict for 
chemotherapy resistance in breast cancer patients.  
3.4.3 ECM/Integrin/mTOR Pathway in Regulating Chemotherapy 
Resistance of Breast Cancer 
In solid tumors, the protective effect of ECM/integrin is mainly mediated via 
integrin β1, which are the most expressed on cancer cells. Furthermore, the 
protective effect of integrin β1 is mediated through activation of the 
PI3k/AKT pathway, which inhibited drug-induced cell cycle arrest and 
apoptosis (55-57). As for breast cancer, gene expression analysis revealed that 
activated ECM/integrin β1/PI3K/Akt pathway played an important role in 
docetaxel resistance in MCF-7 cells (115). In this study, we confirmed that 
two particular ECM components, both THBS1 and TNC, rescued MCF-7 cells 
from docetaxel-induced proliferation arrest through activating integrin 
β1/mTOR pathway and deregulating cell cycle progression. THBS1 and TNC 
in tumor microenvironment may bind to and activate integrin β1 on the 
surface of breast cancer cells to phosphorylate intracellular mTOR pathway. 
Activated mTOR signaling in turn promotes the transcription and translation 
of its downstream effectors cyclin D1 and c-myc as well as degrades p27 to 
promote cell cycle G1/S progression. Our results identify ECM/integrin 
β1/mTOR signaling as an important survival pathway in chemotherapy-
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induced growth inhibition in breast cancer cells and suggest that activation of 
this pathway may contribute to the development of chemotherapy resistance.  
In vivo, we found that doxorubicin- and docetaxel-based neoadjuvant 
chemotherapy induced significant increase in integrin β1 following 2 cycles of 
chemotherapy. In vitro, we showed docetaxel induced decrease in integrin β1 
48 hours after treatment in MCF-7 cells (Figure 3.24). The discordant results 
for integrin β1 between in vivo and in vitro experiments may be explained by 
differential duration of chemotherapy (3 to 6 weeks vs 48 hours) and the 
influence of the tumor microenvironment (present vs absent) to the cancer cell 
response to chemotherapy drugs. A gene expression study showed genes 
related to cell cycle, survival and immune function were immediately up-
regulated 24 to 96 hours after anthracycline-based treatment, but changes of 
focal adhesion-related genes were not seen at these early timepoints following 
chemotherapy (118). Previously, our DNA microarray data revealed that genes 
involved in the focal adhesion pathway were enriched following 3 weeks of 
either doxorubicin or docetaxel treatment (gene expression data from the 
primary cohort of this thesis) (119).  As such, increase in focal adhesion-
related genes may be a relatively late event which requires longer exposure to 
chemotherapy drugs. Moreover, in vitro experiments performed in current 
thesis were 2 dimensional culture-based, with lack of the impact of tumor 
microenvironment on cancer cells which physiologically exists in tumors from 
patients. These may lead to the differences in functional behaviour of cancer 
cells such as invasiveness and gene expression between in vivo and in vitro. 
Previously, we compared doxorubicin-induced gene signatures between 3-
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week treated tumor biopsies and up to 36-hour treated breast cancer cells (119). 
We found that, of the top 500 probe sets that were significantly induced by 
doxorubicin in vivo, only 125 probe sets were found in the in vitro datasets. Of 
these, only 55 probes sets (51 genes) were significantly and concordantly 
induced in vivo and in vitro, and comprised of genes involved in cell cycle, 
DNA replication and repair and stress response. Changes of focal adhesion 
genes were discordant between in vivo and in vitro in response to doxorubicin 
treatment. Therefore, length of chemotherapy given and involvement of tumor 
microenvironment may explain the differential response of integrin β1 upon 
exposure to chemotherapy in vivo and in vitro. 
3.5 Conclusions for CAF/ECM/Integrin Project 
In clinical specimens, we have shown 1) the association between a panel of 
CAF/ECM proteins (THBS1, TNC, FN, SPARC and α-SMA) and their 
corresponding integrin subunits (α6 and β1) with shorter survival; 2) their 
association with chemotherapy resistance following docetaxel- and 
doxorubicin-based neoadjuvant chemotherapy. The association between key 
components of ECM/integrin signaling (THBS1, TNC and integrin α6) and 
chemotherapy resistance was further validated in an independent patient 
population receiving neoadjuvant single docetaxel treatment. Through 
functional studies, we have confirmed that both THBS1 and TNC protected 
MCF-7 cell from proliferation inhibition induced by docetaxel through 
activating integrin β1/mTOR pathway and deregulating cell cycle proteins. 
Taken together, our findings suggest that ECM/integrin/mTOR signalling play 
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an important role in regulating breast cancer progression and chemotherapy 
resistance. Therefore, targeting ECM/integrin β1/mTOR pathway may be a 
promising therapeutic strategy to overcome chemotherapy resistance in breast 
cancer. Currently, several integrin inhibitors such as a humanized anti-β1 
antibody are being tested in clinical trials as therapeutic agents for cancer (56). 
In addition, mTOR inhibitors have been found to be additive or synergistic 
with chemotherapy agents, such as paclitaxel, cisplatin, and doxorubicin (78).  
Randomized phase 3 clinical trials have confirmed the therapeutic effects of 
everolimus, an mTOR inhibitor, in breast cancer patients. For instance, 
everolimus combined with an aromatase inhibitor improved progression-free 
survival in patients with hormone-receptor-positive advanced breast cancer 
compared to an aromatase inhibitor alone (120). Addition of everolimus to 
trastuzumab plus vinorelbine significantly prolongs progression-free survival 
in patients with trastuzumab-resistant and taxane-pretreated, Her2-positive, 
advanced breast cancer (121). As yet, no reliable predictive biomarkers have 
been identified to select patients most likely to benefit from an mTOR 
inhibitor. Our findings suggest that CAF/ECM proteins and integrins may be 
potential biomarkers in breast cancer for response to mTOR inhibition, and 
further studies may be performed to evaluate this.   
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CHAPTER 4. SIMVASTATIN EXERTS ANTI-TUMORAL EFFECTS 
THROUGH DEACTIVATING PI3K/AKT/mTOR AND MAPK/ERK 
PATHWAYS IN BREAST CANCER VIA SUPPRESSING 
MEVALONATE PATHWAY 
4.1 Introduction  
In recent years, statins have attracted attention as potential therapeutic agents 
in various types of cancer, including colon, lung and breast (122-124). A 
recent epidemiological study in a Danish cohort showed a 15% reduction in 
all-cause and cancer-specific mortality in statins users as compared to non-
users (125). Improved survivals with statins exposure were seen in many 
common types of cancer, such as breast cancer (125). In a window-of-
opportunity clinical trial in breast cancer, short term fluvastatin treatment 
exerted anti-tumoral effects by decreasing Ki67 and by increasing cleaved 
caspase-3 expression (126). Another prospective study showed the anti-
proliferation effects of statins to be more significant in HMG-CoA reductase 
positive breast cancer (127). Preclinical studies have also shown that statins 
play an important role in suppressing proliferation, inducing apoptosis and 
inhibiting metastasis of breast cancer (124, 128, 129). However, the precise 
mechanisms by which statins regulate proliferation and apoptosis of breast 
cancer are still unclear. One potential mechanism of the anti-cancer effects of 
statins is the decrease in levels of mevalonate and downstream lipid isoprenoid 
intermediates and the subsequent inhibition of prenylation of Ras and Rho 
proteins mediated through HMG-CoA reductase inhibition. Statins may thus 
suppress downstream signalling pathways of these proteins, such as the 
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PI3K/Akt/mTOR and MAPK/ERK pathways, which are commonly abrogated 
in many types of cancer. 
The biological alterations following statins treatment in prospective clinical 
trials, particularly their potential effects on downstream effectors, are lacking. 
In this study, IHC staining on breast cancer clinical samples treated with 
simvastatin prospectively followed by in vitro functional studies on breast 
cancer cell lines were applied with the following objectives: 1) to explore the 
effects of simvastatin on apoptosis, proliferation and Ras downstream 
pathways including PI3K/Akt/mTOR and MAPK/ERK in a window-of-
opportunity breast cancer trial; and 2) to further confirm findings from the 
clinical trial by functional studies using breast cancer cell lines. These findings 
shed light on the biological and potential therapeutic effects of simvastatin in 
breast cancer. 
4.2 Patients, Materials and Methods 
The patients enrolled and materials and methods used in this project is 








4.2.1 Patient Samples Collected from a Window-of-Opportunity Trial 
15 female patients with newly diagnosed primary breast cancer received 5-38 
days of simvastatin at a dose of 20mg daily before definitive breast cancer 
surgery as part of a window-of-opportunity clinical trial. Pre- and post-
treatment tumor biopsies were obtained before starting simvastatin and at 
surgery, respectively. The clinicopathological characteristics of the patient 
cohort were summarized in Table 4.1.  
Table 4.1 Clinicopathological characteristics of breast cancer patients enrolled 
into a window-of-opportunity study with simvastatin  
4.2.2 IHC Staining 
As described in Section 3.2.3.3, consecutive sections of 4µm thickness were 
cut from pre- and post-treatment tumor samples and stained. Antibodies used 
for IHC staining were listed in Table 4.2. 
Parameters   N (%) 
Age Median age 52.7; range 41 to 70 
Race Chinese 6 (40.0) 
Malay 7 (46.7) 
Indian  1 (6.7) 
Others 1 (6.7) 
Histological tumor type Invasive ductal carcinoma 11 (73.3) 
Invasive lobular carcinoma 2 (13.3) 
Others 2 (13.3) 
Tumor grade 2 8 (53.3) 
3 7 (46.7) 
Estrogen Receptor Negative 3 (20.0) 
Positive 12 (80.0) 
Progesterone Receptor  Negative 3 (20.0) 
Positive 12 (80.0) 
Human Epidermal 
Growth Factor Receptor 2 
Negative 13 (86.7) 
Positive 2 (13.3) 
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Table 4.2 Antibodies used for immunohistochemistry staining of simvastatin 
project 
4.2.3 Scoring of IHC Expression  
As described in Section 3.2.3.4, the expression of cleaved caspase-3, PTEN, p-
Akt, p-S6RP, p-c-Raf and p-ERK1/2 in tumor cells was scored using H-score 
system. Ki67 proliferation index was assessed by calculating Ki67 positive 
tumor nuclei in 500 tumor cells (127).  
4.2.4 Cell Lines and Reagents  
 Human breast cancer cell lines MCF-7 (ER+/Her2-), MDA-MB-231 (ER-
/Her2-) and BT-549 (ER-/Her2-) were purchased from American Type Culture 
Collection (ATCC, Manassas, VA, USA).  MCF-7 and MDA-MB-231 were 
maintained in DMEM and BT-549 was cultured in RPMI 1460 media (Nacalai 
Tesque, Japan), supplemented with 10% FBS and 1X Penicillin-Streptomycin 
(Invitrogen, Carlsbad, CA) at 37°C in a humidified atmosphere with 5% CO2. 
Cell lines were re-authenticated upon receipt. Simvastatin, mevalonate, 
ammonium salt of farnesyl pyrophosphate (FPP) and geranylgeranyl 
pyrophosphate (GGPP) were purchased from Sigma-Aldrich Co (St. Louis, 
MO, USA). Simvastatin was dissolved in DMSO which was used as vehicle 
Antibodies Manufacturers 
Cleaved caspase-3 Cell Signaling Technology  
Ki67 Merck Millipore 
PTEN Cell Signaling Technology  
p-Akt (Ser473) Cell Signaling Technology  
p-S6 ribosomal protein (Ser235/236) Cell Signaling Technology  
p-c-Raf (Tyr340/341) Santa Cruz Biotechnology 
p-ERK1/2 (Thr202/Thy204) Cell Signaling Technology  
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control. Antibodies used for Western blots analysis were listed in Table 4.3. 
All antibodies were purchased from Cell Signaling Technology (Beverly, MA).  
Table 4.3 Antibodies used for Western blots analysis of simvastatin project 










p-Akt (Ser473) 60 
mTOR 289 
p-mTOR (Ser2448) 289 
p70S6K 70,85 
p-p70S6K (Thr389) 70,85 
S6 ribosomal protein (S6RP) 32 
p-S6RP (Ser235/236) 32 
4E-BP1 15-20 
p-4E-BP1 (Thr37/36) 15-20 
c-Raf 65-75 
p-c-Raf (Ser338) 74 
MEK1/2 45 
p-MEK1/2 (Ser217/221) 45 
ERK1/2 42,44 
p-ERK1/2 (Thr202/Tyr204) 42,44 
p90 ribosomal S6 kinases (RSK1-3) 90 
p-p90RSK(Ser380) 90 
β-actin 45 







4.2.5 Cell Treatment 
Cells were seeded in 96-well plates or 10cm dish and treated with simvastatin 
at the indicated concentrations for 24 or 48 hours. To determine if metabolic 
products of the mevalonate pathway, such as mevalonate, FPP and GGPP, 
could block the anti-tumoral effects of simvastatin, cells were pre-treated with 
200µM mevalonate, 10µM FPP and 20µM GGPP respectively for 1 hour and 
then incubated with or without simvastatin for 48 hours, at dosage showing 
significant anti-tumoral effects on breast cancer cells (20µM for MCF-7; 
0.8µM for MDA-231; 10µM for BT-549). All experiments were performed in 
triplicates.  
4.2.6 Caspase-3/7 Assay 
Cells treated in 96-well plates were mixed with 100μl of Caspase-3/7 Reagent 
(Promega, Madison, WI) for 30 minutes. Caspase-3/7 Reagent provides a 
proluminescent caspase-3/7 substrate, which contains the tetrapeptide 
sequence DEVD. This substrate is cleaved to release aminoluciferin, a 
substrate of luciferase to produce light. The caspase-3 and -7 activities were 
assessed using a plate-reading luminometer (Tecan, Männedorf, Switzerland). 
4.2.7 Cell Viability Assay 
As described in Section 3.2.3.7, the viability of cells treated in 96-well plates 
was measured with MTS assay according to the instructions of the 
manufacturer. 
4.2.8 Western Blots Analysis 
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 As described in Section 3.2.3.8, protein level changes of biomarkers of 
interest following simvastatin treatment at the indicated concentrations were 
measured by Western blots analysis.  
4.2.9 Statistical Analysis 
The different immunoreactivity expression of biomarkers between pre- and 
post-treatment tumors was analyzed using paired t-test. The changes of 
caspase 3/7 activity and cell viability by simvastatin treatment on breast 
cancer cells were determined with t-test, compared with the vehicle control. 
The protective effects of mevalonate, FPP and GGPP on breast cancer cells 
were also determined with t-tests by comparing with simvastatin treated cells. 
Statistical analyses were performed using IBM SPSS package (version 19.0 
for Windows, IBM SPSS Inc., USA) with significance at 5%. 
4.3 Results 
4.3.1 Clinical Findings of the Anti-tumoral Effects of Simvastatin in 
Clinical Specimens 
4.3.1.1 Simvastatin Induced Apoptosis and Suppressed Proliferation of 
Breast Cancer in Clinical Specimens 
As shown in Figure 4.2, significant induction of apoptosis determined by 
positive cleaved caspase-3 was seen in post-treatment tumors (8.9±7.4 vs 
23.4±24.3 for pre- vs post-treatment, p=0.002). Decreased trend in Ki67 was 
observed in post-treatment compared to pre-treatment samples, although p-
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value did not reach significance (74.6±59.9 vs 57.7±35.2 for pre- vs post-
treatment, p=0.245).  
 
Figure 4.2 Simvastatin induced apoptosis and inhibited proliferation in a 
window-of-opportunity trial of breast cancer Immunohistochemistry staining was 
performed in paired pre- and post-treatment tumors with simvastatin. (a-c) cleaved 




4.3.1.2 Simvastatin Deactivated PI3K/Akt/mTOR and MAPK/ERK 
Pathways of Breast Cancer in Clinical Specimens  
Simvastatin significantly inhibited PI3K/Akt/mTOR signalling pathway by 
increasing PTEN expression (30.0±46.6 vs 66.1±65.2, p=0.005) and 
decreasing phosphorylation of both Akt at Ser473 and S6RP at Ser235/236 
(93.0±87.4 vs 9.0±19.5, p=0.002 for p-Akt; 108.6±67.7 vs 63.7±51.6, p=0.033 
for p-S6RP; Figure 4.3).  
 
Figure 4.3 Simvastatin deactivated PI3K/Akt/mTOR pathway in a window-of-
opportunity trial of breast cancer  Immunohistochemistry staining was performed 
in paired pre- and post-treatment tumors with simvastatin. (a-c) PTEN; (d-f) phospho-
Akt (Ser 473); (g-i) phospho-S6 ribosomal protein (Ser235/236); Magnification ×200; 




Similarly, simvastatin also deactivated MAPK/ERK pathway by 
dephosphorylating c-Raf at Tyr340/341 and ERK1/2 at Thr202/Thy204 
(107.3±67.1 vs 57.3±51.8, p=0.018 for p-c-Raf and 105.0±73.1 vs 26.6±42.6, 
p=0.002 for p-ERK1/2; Figure 4.4). Taken together, these data indicate that 
simvastatin induces apoptosis and suppresses proliferation probably through 
inactivating PI3K/Akt/mTOR and MAPK/ERK signalling pathways of breast 
cancer.  
 
Figure 4.4 Simvastatin deactivated MAPK/ERK pathway in a window-of-
opportunity trial of breast cancer Immunohistochemistry staining was performed in 
paired pre- and post-treatment tumors with simvastatin. (a-c) phospho-c-Raf 





4.3.1.3 Simvastatin-induced Apoptosis and Suppression of 
PI3K/Akt/mTOR Pathway were Early Events while Deactivation 
of MAPK/ERK pathway was a Later Event in Clinical Specimens  
To further determine the impact of different duration simvastatin exposure on 
the biological effects in breast cancer, patients were divided into two 
subgroups using mean treatment duration of 14 days as cut-off: ≤14 day group 
(mean treatment duration 9.4±3.7, range 5 to 14 days, n=9); >14 day group 
(mean treatment duration 21.5±9.0, range 15 to 38 days, n=6). As shown in 
Figure 4.5, in tumors exposed to simvastatin ≤14 days, simvastatin 
significantly increased apoptosis by enhancing cleaved caspase-3 expression 
(10.5±8.9 vs 18.5±16.6, p=0.039, Figure 4.5a) and deactivated 
PI3K/Akt/mTOR pathway by enhancing PTEN expression (16.3±27.7 vs 
36.9±41.8, p=0.030, Figure 4.5b) and by dephosphorylating both Akt and 
S6RP (106.7±82.5 vs 12.8±24.1 for p-Akt, p=0.006, Figure 4.5c; 132.5±46.5 
vs 56.3±39.6 for p-S6RP, p=0.003, Figure 4.5d). However, no significant 
activity on the MAPK/ERK pathway was observed following short exposure 
to simvastatin ≤14 days (p=0.237 for p-c-Raf change; p=0.069 for p-ERK1/2 
change). As for tumors exposed to simvastatin >14 days, deactivation of Akt 
pathway continues to be observed with enhanced PTEN expression (48.3±62.1 
vs 105.0 ±73.7, p=0.012, Figure 4.5b). Interestingly, deactivation of 
MAPK/ERK pathway was now obvious through dephosphorylation of both c-
Raf and ERK1/2 (113.2±52.0 vs 40.0±39.0, p=0.023 for p-c-Raf, Figure 4.4e; 
118.3±82.3 vs 28.0±33.5, p=0.011 for p-ERK1/2, Figure 4.5f) in these tumors 
that have had longer exposure to simvastatin. These data suggest that 
simvastatin deactivation of PI3K/Akt/mTOR pathway and induction of cell 
121 
 
apoptosis were early events, while deactivation of MAPK/ERK pathway 
appeared to require longer duration exposure to simvastatin in clinical 







Figure 4.5 Association between apoptosis induction and dephosphorylation of 
PI3K/Akt/mTOR and MAPK/ERK pathway and treatment duration of 
simvastatin (a) Cleaved caspase 3; (b) PTEN; (c) p-Akt; (d) p-S6RP; (e) p-c-Raf; (f) 
p-ERK1/2; (g) Schema of the time-points of apoptosis induction and 
dephosphorylation of PI3K/Akt/mTOR and MAPK/ERK pathway during up to 38 
days of simvastatin treatment; * P<0.05; **P<0.01 
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4.3.2 Cellular Findings of the Anti-tumoral Effects of Simvastatin in 
Breast Cancer Cell Lines 
4.3.2.1 Simvastatin Induced Apoptosis of Breast Cancer Cell Lines 
Since we have observed the cytotoxic effects of simvastatin on breast cancer 
in clinical specimens, we then went on to explore its anti-cancer effects in both 
ER-positive (MCF-7) and ER-negative (MDA-MB-231 and BT-549) cell lines. 
Simvastatin increased the activities of caspase-3/7 in a dose dependent manner 
following 48 hours treatment. 50µM simvastatin induced caspase-3/7 by 6-
fold in BT-549, 3-fold in MDA-MB-231 and 2-fold in MCF-7 (Figure 4.6a). 
MCF-7 cells are deficient in the expression of caspase-3 because of a 
spontaneous deletion within the CASP-3 gene (130). This deficiency of 
caspase-3 greatly impairs proteolysis of a range of caspase substrates in MCF-
7 cells, including PARP (131). Therefore, for further validation on apoptosis, 
we focused on MDA-MB-231 and BT-549 cells, in which, to our knowledge, 
caspase mutations were not reported. Using Western blots analysis, we 
confirmed significant cleavage of caspase-8, caspase-3 and PARP in cells 
treated for 48 hours, and obvious dose-dependent cleavages were seen at 
dosages as low as 0.4µM for MDA-MB-231 and 5µM for BT-549 (Figure 
4.6b). Apoptotic data suggest that simvastatin induces apoptosis through both 
enhancing the activities of caspase-3/7 and promoting the cleavage of caspase-





Figure 4.6 Simvastatin induced apoptosis in breast cancer cells (a) MCF-7, MDA-
MB-231 and BT-549 were exposed to simvastatin (range from 0 to 50µM) for 48 
hours and apoptosis was detected by measuring caspase-3/7 activity; (b) After 24 and 
48 hours treatment for MDA-MB-231 (dose from 0 to 0.8µM) and BT-549 (dose 
from 0 to 10µM), apoptosis were determined by Western bolts analysis with 




4.3.2.2 Simvastatin Inhibited Proliferation of Breast Cancer Cell Lines 
Next, we went on to confirm the clinical observations of inhibitory effects of 
simvastatin on breast cancer growth by functional studies. MTS assay showed 
that simvastatin inhibited the growth of MCF-7, MDA-MB-231 and BT-549 in 
a dose dependent manner. Among these 3 cell lines, MDA-MB-231 appears to 
be the most sensitive, with significant inhibition of cell growth seen in cells 
treated at dosage as low as 0.5µM of simvastatin (Figure 4.7a). Western blots 
analysis further confirmed that simvastatin decreased the expression of c-myc 
and cyclin D1 and increased p21 and p27 in a dose dependent manner. 
Significant changes for these cell cycle biomarkers were seen at dosages as 
low as 10, 0.4 and 2.5µM for MCF-7, MDA-MB-231 and BT-549, 
respectively (Figure 4.7b). Taken together, our findings suggest that 
simvastatin deregulate the expression of cell cycle proteins to inhibit cell cycle 






Figure 4.7 Simvastatin inhibited proliferation in breast cancer cells (a) Cells were 
treated with simvastatin (range from 0 to 150µM) for 48 hours and cell viability was 
measured by MTS assay; (b) After 48 hours of simvastatin treatment for MCF-7 
(range from 0 to 20µM), MDA-MB-231 (range from 0 to 0.8µM) and BT-549 (range 
from 0 to 10µM), proliferation was determined by Western blots by assessing the 




4.3.2.3 Simvastatin Deactivated PI3K/Akt/mTOR Pathway in Breast 
Cancer Cell Lines 
We explored the effects of simvastatin on PI3K/Akt/mTOR pathway effectors, 
including PTEN, Akt, mTOR, p70S6K, S6RP and 4E-BP1 (Figure 4.8), in 
breast cancer cell lines. After 48 hours treatment, PTEN expression increased 
in MCF-7 and MDA-MB-231 at dosage as low as 10µM and 0.2µM, 
respectively, in line with a previous report (15). PTEN expression is 
undetectable in BT-549 because it is a PTEN-null cell line (132). It has been 
well known that tumor suppressor PTEN dephosphorylates PIP3 to PIP2, 
thereby terminating PI3K-dependent signalling. Our findings suggest that, in 
PTEN-intact breast cancer cell lines MCF-7 and MDA-MB-231, simvastatin 
suppresses PI3K pathway of breast cancer through enhancing PTEN 
expression and thus inhibits downstream Akt/mTOR signalling. Furthermore, 
in all three cell lines, dose-dependent suppression of phosphorylation was 
noted for Akt at Ser473, mTOR at Ser 2488 and p70S6K at Thr389. Therefore, 
simvastatin treatment blocked PI3K downstream signalling through 
dephosphorylating Akt, mTOR and p70S6K. Moreover, we examined the 
effects of simvastatin on phosphorylation of S6 ribosomal protein, a direct 
target for p70S6K, whose phosphorylation promotes the translation of mRNA 
that has oligopyrimidine tracts in the 5’ untranslated region. Simvastatin 
treatment strongly suppressed phosphorylation of S6 ribosomal protein. We 
also examined the effects of simvastatin treatment on phosphorylation of the 
translational repressor 4E-BP1, a protein that plays a key regulatory role on 
the inhibition of cap-dependent mRNA translation by negatively controlling 
the function of elF4E. Simvastatin treatment of cells significantly suppressed 
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phosphorylation of 4E-BP1 at Thr37/36. Thus, simvastatin appears to 
negatively regulate activation of PI3K/Akt and further block mTOR→S6 
ribosomal protein and →4E-BP1 signalling cascades in breast cancer cells.  
 
Figure 4.8 Simvastatin deactivated PI3K/Akt/mTOR pathways in breast cancer 
cells The levels of total and phosphorylated total proteins of PI3K/Akt/mTOR 
pathway, including PTEN, Akt, mTOR, p70S6K, S6RP and 4E-BP1, were assessed 
by Western blots following 48 hours simvastatin treatment.  
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4.3.2.4 Simvastatin Suppressed MAPK/ERK Pathway in Breast Cancer 
Cells 
To determine the effects of simvastatin on MAPK/ERK pathway, 
phosphorylation of c-Raf at Ser338, MEK1/2 at Ser217/221, ERK1/2 at 
Thr202/Tyr204 and p90RSK at Ser380 were assessed by Western blots 
analysis (Figure 4.9). 10µM simvastatin was required to dephosphorylate c-
Raf in MCF-7, while a much lower concentration of 0.2µM or 2.5µM 
simvastatin started to suppress phosphorylation of c-Raf in MDA-MB-231 and 
BT-549, respectively. In addition, dose-dependent suppression of total c-Raf 
expression was seen in both MDA-MB-231 and BT-549. These data suggest 
that c-Raf is simvastatin-sensitive in breast cancer cells. To further examine if 
downstream effectors of c-Raf would be inhibited by simvastatin, 
phosphorylation levels of MEK1/2, ERK1/2 and p90RSK were assessed by 
immunoblotting. Consistently, dephosphorylation of MEK1/2, ERK1/2 and 
p90RSK was seen in MCF-7 and BT-549 treated with equal to or more than 
10µM and 2.5µM simvastatin, respectively, suggesting that simvastatin 
sequentially deactivate MAPK/ERK pathway in both MCF-7 and BT-549. 
Surprisingly, simvastatin did not show effects on phosphorylation of MEK1/2, 
ERK1/2 and p90RSK in MBA-MD-231, indicating that the anti-tumoral 
effects of simvastatin in MBA-MD-231 is not dependent on MAPK/ERK 
pathway. MDA-MB-231 harbours BRAF (G464V) mutation, which leads to 
constitutive activation of MAPK pathway, and this may have resulted in 




Figure 4.9 Simvastatin deactivated MAPK/ERK pathways in breast cancer cells  
Western blots were applied by assessing levels of total and phosphorylated proteins 
of c-Raf, MEK, ERK and p90RSK to determine the activation of MAPK/ERK 




4.3.2.5 Mevalonate Pathway Contributed to Simvastatin-Induced 
Apoptosis, Proliferation Inhibition and Deactivation of PI3K/Akt 
and MAPK/ERK Pathways in Breast Cancer Cells  
To further determine whether the anti-cancer effects of simvastatin is mediated 
by the blocking of mevalonate pathway, we performed add-back experiments 
using mevalonate, and two intermediates of the mevalonate pathway, FPP or 
GGPP. MCF-7, MDA-MB-231 and BT-549 cells were pre-treated with 
mevalonate, FPP or GGPP, followed by simvastatin treatment for 48 hours. 
Mevalonate, FPP and GGPP could reverse the levels of caspase-3/7 close to 
that in vehicle control for all three cell lines (P<0.05 for mevalonate, FPP and 
GGPP versus simvastatin treatment respectively, Figure 4.10). Similarly, MTS 
assay showed that mevalonate, FPP and GGPP were able to block simvastatin-
inhibited growth of all three cell lines (P<0.05 for mevalonate, FPP and GGPP 
versus simvastatin treatment respectively, Figure 4.11). We went on to 
determine the effects of mevalonate and its metabolites on PI3k/Akt and 
MAPK/ERK pathway by Western blot analysis. Figures 4.12 showed that 
simvastatin-induced dephosphorylation of Akt at Ser473 and ERK1/2 at 
Thr202/Tyr204 were markedly blocked by mevalonate, FPP and GGPP 
respectively. Therefore, depletion of mevalonate, FPP and GGPP by 
simvastatin contributes to simvastatin-induced apoptosis promotion, 





Figure 4.10 Simvastatin-induced apoptosis was blocked by mevalonate, FPP and 
GGPP MCF-7, MDA-MD-231 and BT-549 were pre-treated with mevalonate 
(200μM), FPP (10μM) and GGPP (20μM) for 1 hour respectively, followed by 
incubation with or without simvastatin (20μM for MCF-7; 0.8μM for MDA-MB-231 





Figure 4.11 Simvastatin-inhibited cell growth was blocked by mevalonate, FPP 
and GGPP MCF-7, MDA-MD-231 and BT-549 were pre-treated with mevalonate 
(200μM), FPP (10μM) and GGPP (20μM) for 1 hour respectively, followed by 
incubation with or without simvastatin (20μM for MCF-7; 0.8μM for MDA-MB-231 




Figure 4.12 Simvastatin-deactivated PI3K/Akt and MAPK/ERK pathways were 
blocked by mevalonate, FPP and GGPP MCF-7, MDA-MD-231 and BT-549 were 
pre-treated with mevalonate (200μM), FPP (10μM) and GGPP (20μM) for 1 hour 
respectively, followed by incubation with or without simvastatin (20μM for MCF-7; 
0.8μM for MDA-MB-231 and 10μM for BT-549) for 48 hours. The phosphorylation 




The findings for this part of the thesis are summarized in Figure 4.13. 
 
Figure 4.13 Schema of the anti-cancer effects of simvastatin in breast 
cancer Simvastatin targets mevalonate pathway and thus induces apoptosis and 
inhibits proliferation through suppression of PI3K/Akt/mTOR and MAPK/ERK 





In this study, clinical samples treated prospectively along with in vitro 
functional studies concordantly show simvastatin to induce apoptosis and 
suppress proliferation by dephosphorylating sequential signalling cascades of 
PI3K/Akt/mTOR and MAPK/ERK pathways of breast cancer. In breast cancer 
cell lines, simvastatin-induced anti-tumoral effects are blocked by metabolic 
products of the mevalonate pathway, such as mevalonate, FPP and GGPP. 
4.4.1 The Anti-apoptosis Effects of Simvastatin in Breast Cancer 
Statins have been shown to induce apoptosis through both extrinsic and 
intrinsic pathways, leading to cell death (19, 20). Our clinical data showed that 
simvastatin significantly induced apoptosis measured by cleaved caspase-3, 
which was noted early in tumors following short exposure to simvastatin of 
mean duration of 9.7 days. Consistently, a previous prospective study found 
that fluvastatin treatment increased apoptotic activity in high-grade breast 
cancer (126). In functional studies, we also confirmed the apoptotic effects of 
simvastatin through increasing activities of caspase-3 and caspase-7 as well as 
through proteolytic cleavage of caspase-8, caspase-3 and PARP, in line with  
previous reports that lovastatin induced apoptosis by increasing cellular 
activities of caspase cascades in both lung and prostate cancer (133, 134). 




4.4.2 The Proliferation Inhibition Effects of Simvastatin in Breast 
Cancer 
Previous studies have proved that statins inhibited cellular proliferation 
through the induction of G1/S-arrest in breast cancer (133, 135, 136). In post-
treatment biopsies, we found decreased trend for proliferation determined by 
Ki67, consistent with a previous report in clinical specimens (126). Functional 
studies further confirmed that simvastatin inhibited proliferation of breast 
cancer cells, as evidenced by decrease in both c-myc and cyclin D1 and 
increase in both p21 and p27 in a dose-dependent manner.  
Previous functional, proteomic and metabonomic profiling studies have shown 
relatively higher sensitivity to statins of estrogen receptor (ER)-negative 
MDA-MB-231 breast cancer cells (136-138). Concordant with these reports, 
we showed that ER-negative MDA-MB-231 and BT-549 cell lines were 
indeed more sensitive to simvastatin treatment than ER-positive MCF-7, 
although we found no association between ER status and sensitivity to 
simvastatin in the clinical specimens, which may be attributed to the relatively 
small sample size for ER-negative tumors (n=3). Although we still are unclear 
why statins appear more active in ER-negative breast cancers, these findings 
suggest that simvastatin could be a rational therapeutic strategy for ER-
negative breast cancers. 




Simvastatin is believed to serve as a prenylation inhibitor in cancer treatment 
as it inhibits HMG-CoA reductase of mevalonate pathway and thus suppresses 
protein prenylation (33). Several studies have shown that prenylation 
inhibitors of mevalonate pathway affect oncogenic and survival signal 
transduction pathways (139), which can explain some of the anti-tumour 
effects of statins. Constitutive activation of the PI3K/Akt/mTOR and 
MAPK/ERK pathways is an important event in breast cancer (34, 46). 
Therefore, we explored the effects of simvastatin on these pathways which are 
of potentially high relevance to breast cancer. In clinical specimens, 
simvastatin enhanced PTEN expression and dephosphorylated Akt at Ser473 
and S6RP at Ser235/236, following relatively short duration exposure (mean 
9.7 days). In cell lines, we found that simvastatin consistently inhibited the 
sequential activation of PI3K→Akt→mTOR→S6 ribosomal protein and →
4E-BP1 signalling cascade through enhancing PTEN expression in PTEN-
intact MCF-7 and MDA-MB-231cells in a dose-dependent manner. 
Interestingly, for PTEN-null BT-549, similar inhibitory effects on PTEN 
downstream signalling of Akt/mTOR were still observed, suggesting that 
simvastatin is able to mediate other alternative effectors to inhibit Akt/mTOR 
signalling in PTEN-null tumors. In malignant cells, epidermal growth factor 
receptor (EGFR) and its downstream signalling pathways often are 
deregulated, leading to enhanced cell growth. Mevalonate metabolites 
potentially mediate the function of the EGFR signalling pathway through 
regulation of prenylation of Ras, Rho and Rab families (140). For example, 
depletion of mevalonate metabolites through inhibition of HMG-CoA 
reductase resulted in inhibition of EGFR and downstream Akt signalling (141-
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143). Moreover, Zhao et al (144) showed that lovastatin inhibited EGFR 
dimerization and deactivated Akt in squamous cell carcinoma cells through 
regulation of Rho A proteins. EGFR is overexpressed in many cancer types 
including ~30% of breast cancers. EGFR was expressed and tyrosine active in 
BT-549 (141). Therefore, we speculate that, in PTEN-null BT-549 cells, 
simvastatin may inhibit EGFR and its downstream Ras or Rho to deactivate 
downstream PI3K/Akt/mTOR pathway, which warrants further investigation. 
Therefore, simvastatin-suppressed PI3K/Akt/mTOR pathway may be through 
differential mechanisms in PTEN-intact and -null breast cancer. Collectively, 
in both clinical specimens and cell lines, we concordantly found that 
simvastatin deregulated the activation of several important components of 
PI3K/Akt/mTOR pathway, indicating that PI3K/Akt/mTOR pathway is one of 
the targets of simvastatin in breast cancer.  
4.4.4 The Inactivation of MAPK/ERK Pathway by Simvastatin in 
Breast Cancer 
The MAPK/ERK pathway is another signalling pathway which transmits 
signals from the cell surface receptors to nuclear transcription factors. 
MAPK/ERK pathways are known to be more activated in approximately half 
of breast cancer compared to the surrounding benign tissue. These may be the 
result from enhancement of growth factor pathway activation (45). In breast 
cancer clinical specimens and cell lines, we concordantly showed that 
simvastatin inhibited the activation of important components of MAPK/ERK 
pathway, such as c-Raf and ERK1/2. In clinical specimens, inhibition of 
MAPK/ERK appeared to be a late event, occurring only after mean duration of 
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simvastatin exposure of about 3 weeks, compared to the early effects observed 
on the PI3K/Akt/mTOR pathway. The sequential suppression of the 
MAPK/ERK pathway was further confirmed by dose-dependent 
dephosphorylation of c-Raf at Ser338, MEK1/2 at Ser217/221, ERK1/2 at 
Thr202/Tyr204 and p90RSK at Ser380 in both MCF-7 and BT-549, although 
the inhibitory effects on the phosphorylation of c-Raf downstream effectors 
were not obvious in MDA-MB-231. Up to 0.8μM simvastatin treatment for 48 
hours may not be optimal dosage and duration for MDA-MB-231 to suppress 
the constitutive activation of MAPK pathway caused by BRAF (G464V) 
mutation in this cell line, and higher simvastatin dose and/or longer exposure 
may be required for tumors with BRAF mutations. In addition, we found dose-
dependent decrease in c-Raf expression in both MDA-MB-231 and BT-549, 
suggesting that, apart from dephosphorylation of c-Raf, suppression of c-Raf 
expression may account for the anti-tumor effects of simvastatin in a 
subpopulation of breast cancer patients. Our findings in breast cancer are in 
line with previous reports on other cancers, including leukaemia and renal cell 
carcinoma, in which statins resulted in significant disruption of ERK1/2 
phosphorylation (32, 33). These data suggest that MAPK/ERK is another 
target pathway of simvastatin in cancer, which can explain, at least partially, 
the apoptosis induction and anti-proliferation effects of statins.  
4.4.5 The Clinical Significance of Dual Inactivation of both 
PI3K/Akt/mTOR and MAPK/ERK Pathways by Simvastatin in 
Breast Cancer 
The presence of concurrent multiple activated signalling pathways contribute 
to the heterogeneous nature of breast cancer that thus necessitate multi-
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targeted approaches for effective breast cancer prevention and therapy. In 
breast cancer, constitutive activation of both PI3K/Akt/mTOR and 
MAPK/ERK pathways is an important event, which regulates multiple cellular 
processes to promote cancer cell growth, survival, and metastasis (34, 46). An 
emerging therapeutic concept is targeting of two different signal transduction 
pathways, for example, Raf/MEK/ERK and PI3K/Akt/mTOR. This has been 
explored in some preclinical models as well as clinical trials. In previous 
preclinical studies, dual inhibition of PI3K/Akt/mTOR and MAPK/ERK 
pathways by combining different small molecule kinase inhibitors lead to 
more efficient growth inhibition than single pathway inhibition in both breast 
and lung cancers (145, 146).  Indeed, a recent phase I clinical trial in patients 
with advanced cancers confirmed that dual blockade of both 
PI3K/AKT/mTOR and MEK/ERK pathways resulted in favourable efficacy 
compared to single blockade of either pathway (147). This is probably due to 
the interconnection between PI3K and MAPK pathway with multiple points of 
convergence, cross-talk, and feedback loops. For example, ERK1/2 converges 
on mTORC1 via P90RSK, leading to nuclear transcriptional changes that 
regulate cell proliferation and survival (148). Therefore, inhibition of one 
pathway can still result in the maintenance of signalling via the other pathway, 
making inhibition of both PI3K and MAPK pathway a rational therapeutic 
approach. However, dual blockade of both PI3K/AKT/mTOR and MEK/ERK 
pathways by combining small molecule kinase inhibitors were usually 
achieved at the expense of higher toxicity and financial cost (147). Developing 
a safe therapeutic agent that has multiple targets is thus an attractive 
alternative. In this study, we found simvastatin to induce apoptosis and inhibit 
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proliferation of breast cancer by deactivating sequential cascades of both 
PI3K/Akt/mTOR and MAPK/ERK pathways. Simvastatin is cheap, safe, and 
well-tolerated, with a long track record of clinical use in the treatment of 
hypercholesterolemia. Thus, simvastatin has the potential to be used as a 
multi-targeted agent to inhibit both PI3K/AKT/mTOR and MEK/ERK 
signalling and consequently suppress tumour growth.             
4.4.6 The Suppression of Mevalonate Pathway by Simvastatin in Breast 
Cancer 
Mevalonate pathway, also defined as cholesterol synthesis pathway, plays an 
important role in breast carcinogenesis, growth and metastasis. Exogenous 
expression of HMG-CoA reductase deregulates the mevalonate pathway and 
facilitates transformation in human breast cancer cell lines (149). 27HC, a 
primary metabolite of cholesterol, promotes tumor growth and metastasis in 
mouse models of breast cancer (150). Thus, blocking mevalonate pathway 
may be a useful strategy for breast cancer prevention or treatment. Simvastatin 
is a HMG-CoA reductase inhibitor and suppresses the generation of 
mevalonate, FPP and GGPP and further deregulates cholesterol biosynthesis 
and protein prenylation (33). Protein prenylation is a lipid post-translational 
modification which directs the membrane localization of proteins, such as Ras 
GTPases (33, 139). Consistent with previous findings in lymphoma (151) and 
colorectal cancer (152), we showed that individual add-back with mevalonate, 
FPP and GGPP was able to reverse simvastatin-induced apoptosis promotion, 
proliferation inhibition and deactivation of PI3k/Akt and MAPK/ERK 
signalling in breast cancer cell lines. These data indicate that simvastatin 
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treatment results in the depletion of mevalonate, FPP and GGPP in breast 
cancer cells and subsequently deregulates PI3k/Akt and MAPK/ERK 
signalling pathway and further induces apoptosis and inhibit proliferation of 
cancer cells. Mevalonate pathway contributes to the anti-tumoral effects of 
simvastatin in breast cancer probably through inhibiting protein prenylation. 
Further studies using proteome-wide or prenylome-wide approaches may be 
performed to identify the subsets of prenylated proteins that are modified by 
simvastatin, which in turn could help to link the biological effects of 
simvastatin to their molecular targets, and thus will help in the design of 
rational simvastatin-based therapeutic strategies. 
4.5 Conclusion for Simvastatin Project  
In this study, breast cancer clinical samples treated prospectively along with in 
vitro functional studies in breast cancer cell lines concordantly show 
simvastatin to target the mevalonate pathway and induce apoptosis and inhibit 
proliferation through the suppression of PI3K/Akt/mTOR and MAPK/ERK 
pathways in breast cancer. The findings shed light on the biological effects 
and mechanism of action of simvastatin in breast cancer, which can form the 
basis for future clinical trials design. We acknowledge, in a real world setting, 
that simvastatin is not the most potent statin in terms of reducing the levels of 
low density lipoprotein-cholesterol. Dose-for-dose, rosuvastatin and 
atorvastatin are more effective than simvastatin (153). However, despite its 
relatively lower potency and the low dose used, simvastatin still can exert 
systemic anti-tumoral effects, as shown by our findings in the window-of-
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opportunity clinical trial.  To date, simvastatin has shown the most evidence of 
potential anti-cancer efficacy in both clinical and pre-clinical studies (154-
158), and would be a potential candidate drug in future statins-based 
therapeutic clinical trials. Breast cancer is a clinically heterogeneous disease 
with four different intrinsic molecular subtypes. The different molecular 
classes of breast cancer show different sensitivities to chemotherapy, 
endocrine therapy and biological agents. An emerging concept is that the 
combined inhibition of vital signal transduction pathways together with 
standard therapy might enhance anticancer effect. Simvastatin could be a 
potential drug to be combined with conventional breast cancer therapy drugs, 
including chemotherapy drugs (anthracycline and taxane) for triple-negative 
subtype, endocrine therapy (tamoxifen and aromatase inhibitors) for ER-
positive subtype and targeting Her2 drugs (trastuzumab) for Her2-positive 
subtype cancer. Preclinical studies showed that fluvastatin combined with 
anthracycline (epirubicin) or trastuzumab demonstrated synergistic effects in 
breast cancer cell lines (159). Data for the combined effects of simvastatin and 
standard therapy for breast cancer are limited. Further studies to explore the 
combined effects of simvastatin with common therapeutic drugs (cytotoxic, 




CHAPTER 5. CONCLUSIONS AND FUTURE STUDIES  
Chemotherapy is one of the conventional treatments for breast cancer patients. 
However, both intrinsic and acquired resistance exists, resulting in eventual 
tumor progression in many patients. Reliable predictors of chemotherapy 
resistance could allow early identification of patients who will benefit from 
alternative therapies. In the first part of the thesis, we have shown that increase 
in a panel of CAF/ECM/integrin proteins following neoadjuvant 
chemotherapy was associated with chemotherapy resistance. Therefore, 
CAF/ECM proteins THBS1, TNC, FN, SPARC and α-SMA as well as integrin 
proteins α6 may be potential predictors to stratify patients into sensitive or 
resistant subgroups in response to chemotherapy.  
We further elucidated the underlying mechanisms by which ECM/integrin 
signalling regulated chemoresistance in breast cancer cells through showing 
that both exogenous THBS1 and TNC activated integrin β1/mTOR signalling 
upon exposure to cytotoxic drug. ECM/integrin/mTOR signalling pathway can, 
therefore, constitute a pathway contributing to treatment resistance and tumor 
relapse. Targeting this signalling pathway is a promising strategy to improve 
anti-cancer therapy and patient survival. The potential druggable targets in this 
pathway include integrin β1 and mTOR. Several humanized antibodies 
targeting integrin β1-contained receptors are being developed as therapeutic 
agents for cancer (2). Several mTOR inhibitors (sirolimus, everolimus, 
temirolimus and ridaforolimus) have also demonstrated antitumor activity in 
preclinical studies and in clinical trials of breast cancer (120, 121, 160). 
Preclinical and clinical studies which incorporate integrin β1/mTOR therapy 
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together with chemotherapy could directly address if combined 
integrin/mTOR therapy could overcome chemotherapy resistance. 
In the second part of this thesis, we showed simvastatin to promote apoptosis 
and suppress proliferation by deactivating signalling pathways of breast cancer, 
including PI3K/Akt/mTOR and MAPK/ERK, through inhibition of 
mevalonate pathway. Our understanding on the downstream prenylated 
proteins modified by simvastatin is limited. The identification of these crucial 
simvastatin-prenylated proteins would help us to understand the exact 
mechanisms by which simvastatin induces these anti-cancer effects, which in 
turn will help to design improved simvastatin-base therapeutic strategies. 
Further studies using proteome-wide or prenylome-wide approaches are 
needed to identify the subsets of prenylated proteins that are modified by 
simvastatin. 
Taken together, there is potential to integrate the current findings to design 
novel therapeutic regimens for breast cancer. The first project shows that the 
mTOR pathway plays a role in regulation of chemotherapy resistance in breast 
cancer while the second project confirms that simvastatin induces apoptosis of 
breast cancer cells and deactivates both Akt/mTOR and MAPK/ERK pathway 
as a dual signalling pathway inhibitor. Although mTOR inhibitors such as 
everolimus has been successfully developed in hormone receptor positive 
breast cancer in combination with endocrine therapy, everolimus is expensive 
and its safety profile is still needed to be observed in clinical setting. In 
contrast, simvastatin is cheap with long track record of safety profile in 
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clinical setting. Therefore, simvastatin has the potential to be developed as a 
mTOR inhibitor to overcome chemotherapy resistance in breast cancer. 
Prospective trials which incorporate simvastatin together with chemotherapy 
in breast cancer will be interesting to directly address if incorporating 
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